Ignite Creation Date:
2025-12-24 @ 3:25 PM
Ignite Modification Date:
2026-03-08 @ 11:26 PM
Study NCT ID:
NCT02702492
Status:
TERMINATED
Last Update Posted:
2024-11-25
First Post:
2016-03-03
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA)
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D008545', 'term': 'Melanoma'}], 'ancestors': [{'id': 'D018358', 'term': 'Neuroendocrine Tumors'}, {'id': 'D017599', 'term': 'Neuroectodermal Tumors'}, {'id': 'D009373', 'term': 'Neoplasms, Germ Cell and Embryonal'}, {'id': 'D009370', 'term': 'Neoplasms by Histologic Type'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D009380', 'term': 'Neoplasms, Nerve Tissue'}, {'id': 'D018326', 'term': 'Nevi and Melanomas'}, {'id': 'D012878', 'term': 'Skin Neoplasms'}, {'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D012871', 'term': 'Skin Diseases'}, {'id': 'D017437', 'term': 'Skin and Connective Tissue Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C000622300', 'term': 'KPT-9274'}, {'id': 'D000077594', 'term': 'Nivolumab'}], 'ancestors': [{'id': 'D061067', 'term': 'Antibodies, Monoclonal, Humanized'}, {'id': 'D000911', 'term': 'Antibodies, Monoclonal'}, {'id': 'D000906', 'term': 'Antibodies'}, {'id': 'D007136', 'term': 'Immunoglobulins'}, {'id': 'D007162', 'term': 'Immunoproteins'}, {'id': 'D001798', 'term': 'Blood Proteins'}, {'id': 'D011506', 'term': 'Proteins'}, {'id': 'D000602', 'term': 'Amino Acids, Peptides, and Proteins'}, {'id': 'D012712', 'term': 'Serum Globulins'}, {'id': 'D005916', 'term': 'Globulins'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'clinicaltrials@karyopharm.com', 'phone': '(888) 209-9326', 'title': 'Karyopharm Medical Information', 'organization': 'Karyopharm Therapeutics Inc'}, 'certainAgreement': {'piSponsorEmployee': False, 'restrictiveAgreement': True}, 'limitationsAndCaveats': {'description': 'Study was terminated prematurely due to a lack of efficacy during primary analysis and therefore, efficacy, PK and PDn assessments were not determined.'}}, 'adverseEventsModule': {'timeFrame': 'From start of study drug administration up to 49 weeks', 'eventGroups': [{'id': 'EG000', 'title': 'Part A: KPT-9274 10mg', 'description': 'Participants received 10 milligrams (mg) of oral tablets of KPT-9274 three times a week every other day during each 28 day cycle.', 'otherNumAtRisk': 3, 'deathsNumAtRisk': 3, 'otherNumAffected': 3, 'seriousNumAtRisk': 3, 'deathsNumAffected': 2, 'seriousNumAffected': 0}, {'id': 'EG001', 'title': 'Part A: KPT-9274 20mg', 'description': 'Participants received 20mg of oral tablets of KPT-9274 three times a week every other day during each 28 day cycle.', 'otherNumAtRisk': 3, 'deathsNumAtRisk': 3, 'otherNumAffected': 2, 'seriousNumAtRisk': 3, 'deathsNumAffected': 2, 'seriousNumAffected': 2}, {'id': 'EG002', 'title': 'Part A: KPT-9274 30mg', 'description': 'Participants received 30mg of oral tablets of KPT-9274 three times a week every other day during each 28 day cycle.', 'otherNumAtRisk': 5, 'deathsNumAtRisk': 5, 'otherNumAffected': 5, 'seriousNumAtRisk': 5, 'deathsNumAffected': 3, 'seriousNumAffected': 2}, {'id': 'EG003', 'title': 'Part A: KPT-9274 40mg', 'description': 'Participants received 40mg of oral tablets of KPT-9274 three times a week every other day during each 28 day cycle.', 'otherNumAtRisk': 7, 'deathsNumAtRisk': 7, 'otherNumAffected': 7, 'seriousNumAtRisk': 7, 'deathsNumAffected': 5, 'seriousNumAffected': 3}, {'id': 'EG004', 'title': 'Part A: KPT-9274 40mg BIW', 'description': 'Participants received KPT-9274 40mg of oral tablet biweekly (BIW) during each 28-day cycle.', 'otherNumAtRisk': 5, 'deathsNumAtRisk': 5, 'otherNumAffected': 5, 'seriousNumAtRisk': 5, 'deathsNumAffected': 1, 'seriousNumAffected': 0}, {'id': 'EG005', 'title': 'Part B: KPT-9274 30mg + Niacin 500mg', 'description': 'Participants received KPT-9274 30mg of oral tablet along with a starting dose of 500mg niacin ER orally three times a week every other day during each 28-day cycle.', 'otherNumAtRisk': 3, 'deathsNumAtRisk': 3, 'otherNumAffected': 3, 'seriousNumAtRisk': 3, 'deathsNumAffected': 3, 'seriousNumAffected': 1}, {'id': 'EG006', 'title': 'Part B: KPT-9274 40mg + Niacin 500mg', 'description': 'Participants received KPT-9274 40mg of oral tablet along with a starting dose of 500mg niacin ER orally three times a week every other day during each 28-day cycle.', 'otherNumAtRisk': 4, 'deathsNumAtRisk': 4, 'otherNumAffected': 4, 'seriousNumAtRisk': 4, 'deathsNumAffected': 3, 'seriousNumAffected': 1}, {'id': 'EG007', 'title': 'Part B: KPT-9274 60mg + Niacin 500mg', 'description': 'Participants received KPT-9274 60mg of oral tablet along with a starting dose of 500mg niacin ER orally three times a week every other day during each 28-day cycle.', 'otherNumAtRisk': 12, 'deathsNumAtRisk': 12, 'otherNumAffected': 12, 'seriousNumAtRisk': 12, 'deathsNumAffected': 6, 'seriousNumAffected': 6}, {'id': 'EG008', 'title': 'Part B: KPT-9274 80mg + Niacin 500mg', 'description': 'Participants received KPT-9274 80mg of oral tablet along with a starting dose of 500mg niacin ER orally three times a week every other day during each 28-day cycle.', 'otherNumAtRisk': 7, 'deathsNumAtRisk': 7, 'otherNumAffected': 7, 'seriousNumAtRisk': 7, 'deathsNumAffected': 4, 'seriousNumAffected': 1}, {'id': 'EG009', 'title': 'Experimental: Part B: KPT-9274 100mg + Niacin 500mg', 'description': 'Participants received KPT-9274 100mg of oral tablet along with a starting dose of 500mg niacin ER orally three times a week every other day during each 28-day cycle.', 'otherNumAtRisk': 1, 'deathsNumAtRisk': 1, 'otherNumAffected': 1, 'seriousNumAtRisk': 1, 'deathsNumAffected': 1, 'seriousNumAffected': 1}, {'id': 'EG010', 'title': 'Part C: KPT-9274 20mg + Nivolumab 480mg', 'description': 'Participants received KPT-9274 20mg of oral tablet three times a week every other day during each 28-day cycle along with 480mg of nivolumab intravenous infusion on Day 1 of each cycle (once every 4-week cycle).', 'otherNumAtRisk': 1, 'deathsNumAtRisk': 1, 'otherNumAffected': 1, 'seriousNumAtRisk': 1, 'deathsNumAffected': 1, 'seriousNumAffected': 1}, {'id': 'EG011', 'title': 'Part C: KPT-9274 30mg + Nivolumab 480mg', 'description': 'Participants received KPT-9274 30mg of oral tablet three times a week every other day during each 28-day cycle along with 480mg of nivolumab intravenous infusion on Day 1 of each cycle (once every 4-week cycle).', 'otherNumAtRisk': 5, 'deathsNumAtRisk': 5, 'otherNumAffected': 5, 'seriousNumAtRisk': 5, 'deathsNumAffected': 2, 'seriousNumAffected': 2}, {'id': 'EG012', 'title': 'Part C: KPT-9274 40mg + Nivolumab 480mg', 'description': 'Participants received KPT-9274 40mg of oral tablet three times a week every other day during each 28-day cycle along with 480mg of nivolumab intravenous infusion on Day 1 of each cycle (once every 4-week cycle).', 'otherNumAtRisk': 4, 'deathsNumAtRisk': 4, 'otherNumAffected': 4, 'seriousNumAtRisk': 4, 'deathsNumAffected': 3, 'seriousNumAffected': 2}], 'otherEvents': [{'term': 'Anaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 5}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 7}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 5}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 2}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 8}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 7}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 1}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 5}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 4}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Abdominal pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 3}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 3}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 2}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Thrombocytopenia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 2}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 3}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 3}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Leukopenia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 1}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Tachycardia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 1}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Hypothyroidism', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 1}], 'organSystem': 'Endocrine disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Constipation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 2}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 2}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 5}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Dyspepsia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 1}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Nausea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 4}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 3}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 3}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 6}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 5}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Small intestinal obstruction', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Vomiting', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 2}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 3}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 4}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 3}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Fatigue', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 2}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 4}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 2}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 2}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 2}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 4}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 5}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 2}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 2}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Oedema peripheral', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 2}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 1}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Pyrexia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 3}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 2}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Hyperbilirubinaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 2}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 1}], 'organSystem': 'Hepatobiliary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Clostridium difficile infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Pneumonia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 2}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Skin infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 1}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Wound infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 1}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Blood alkaline phosphatase increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 1}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Weight decreased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 3}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 1}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Decreased appetite', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 2}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 2}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 2}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 1}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 1}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 1}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Dehydration', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 2}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 1}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 1}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Hypercreatininaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 1}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Hypokalaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 3}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 1}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Arthralgia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 3}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 5}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 2}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 2}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 2}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 3}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 2}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Myalgia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 2}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 2}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 2}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 2}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Back pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 1}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Bursitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 1}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Presyncope', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 1}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Vaginal haemorrhage', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 1}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Reproductive system and breast disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Dyspnoea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 3}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 3}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 4}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 1}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 2}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Haemoptysis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 1}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 1}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Pleural effusion', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 1}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Wheezing', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 1}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Skin burning sensation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 1}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Skin exfoliation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 1}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Hot flush', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 1}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Anaemia of malignant disease', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Leukocytosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Lymphopenia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Thrombocytosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Sinus tachycardia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 2}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Bradycardia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Atrial fibrillation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Pupils unequal', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Eye disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Abdominal distension', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Anal incontinence', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Flatulence', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Gastrointestinal pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Gingival pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Haematochezia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Toothache', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Influenza like illness', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Chest discomfort', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Chills', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Hepatic vein thrombosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Hepatobiliary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Jaundice cholestatic', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Hepatobiliary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Portal vein thrombosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Hepatobiliary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Bronchitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Nasopharyngitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 2}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Urinary tract infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 2}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Procedural pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Aspartate aminotransferase increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 2}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Activated partial thromboplastin time prolonged', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Alanine aminotransferase increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Blood iron decreased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Blood thyroid stimulating hormone increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Lipase increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 2}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Reticulocyte count decreased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Hypomagnesaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 2}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 2}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Hypoalbuminaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 2}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 1}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Hyperamylasaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Hyponatraemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 2}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Muscular weakness', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 2}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Arthritis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Joint effusion', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Joint swelling', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Muscle spasms', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 2}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Musculoskeletal stiffness', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Pain in extremity', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Dizziness', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 2}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 2}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Depressed level of consciousness', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Headache', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Myoclonus', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Neuropathy peripheral', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Nystagmus', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Paraesthesia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Tremor', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Insomnia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Depression', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Irritability', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Proteinuria', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Haematuria', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Micturition urgency', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Pollakiuria', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Urinary incontinence', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Erectile dysfunction', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Reproductive system and breast disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Vaginal discharge', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Reproductive system and breast disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Cough', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 3}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 2}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Nasal congestion', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Hypoxia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Oropharyngeal pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Rhinorrhoea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Pruritus', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 2}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 3}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Alopecia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Night sweats', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Onychoclasis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Flushing', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 2}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 5}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 2}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Deep vein thrombosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Hypotension', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 1}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Lymphoedema', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Cardiomegaly', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Diarrhoea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 2}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 4}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 2}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 3}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 2}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 1}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 2}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Abdominal discomfort', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 2}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Dry mouth', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Ascites', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Upper respiratory tract infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Abdominal infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Campylobacter infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Escherichia bacteraemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Lyme disease', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Oral candidiasis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Fall', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Incision site pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Thermal burn', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Wound dehiscence', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Vitamin B12 decreased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Blood creatine phosphokinase increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Glucose urine present', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Hypercalcaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 2}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Hypophosphataemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 2}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Hyperglycaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Hyperuricaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Hyperkalaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Bone pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Joint range of motion decreased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Musculoskeletal chest pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Musculoskeletal discomfort', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Tumour haemorrhage', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Balance disorder', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Hypoaesthesia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Neuralgia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Confusional state', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Acute kidney injury', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Urinary retention', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Rhinitis allergic', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Rash maculo-papular', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Dry skin', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Erythema', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Rash papular', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Generalised oedema', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Non-cardiac chest pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}], 'seriousEvents': [{'term': 'Anaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 2}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 2}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Thrombocytopenia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 1}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Small intestinal obstruction', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Death', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 1}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Dyspnoea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 1}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Pleural effusion', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 1}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Haematoma', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 1}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Bradycardia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Sinus tachycardia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Abdominal pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 2}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Gastrointestinal haemorrhage', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Intestinal obstruction', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Fatigue', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Pyrexia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Klebsiella bacteraemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Sepsis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Cardiac murmur', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Decreased appetite', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Hypoglycaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Hypokalaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Tumour pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Intracranial mass', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Hyperbilirubinaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Hepatobiliary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Portal vein thrombosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Hepatobiliary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Campylobacter infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Clostridium difficile infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Upper respiratory tract infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Hyperglycaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}, {'term': 'Orthostatic hypotension', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 23.1'}], 'frequencyThreshold': '0'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Maximum Tolerated Dose (MTD) for KPT-9274', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}, {'value': '3', 'groupId': 'OG001'}, {'value': '5', 'groupId': 'OG002'}, {'value': '7', 'groupId': 'OG003'}, {'value': '5', 'groupId': 'OG004'}, {'value': '3', 'groupId': 'OG005'}, {'value': '4', 'groupId': 'OG006'}, {'value': '12', 'groupId': 'OG007'}, {'value': '7', 'groupId': 'OG008'}, {'value': '1', 'groupId': 'OG009'}, {'value': '1', 'groupId': 'OG010'}, {'value': '5', 'groupId': 'OG011'}, {'value': '4', 'groupId': 'OG012'}]}], 'groups': [{'id': 'OG000', 'title': 'Part A: KPT-9274 10mg', 'description': 'Participants received 10 milligrams (mg) of oral tablets of KPT-9274 three times a week every other day during each 28 day cycle.'}, {'id': 'OG001', 'title': 'Part A: KPT-9274 20mg', 'description': 'Participants received 20mg of oral tablets of KPT-9274 three times a week every other day during each 28 day cycle.'}, {'id': 'OG002', 'title': 'Part A: KPT-9274 30mg', 'description': 'Participants received 30mg of oral tablets of KPT-9274 three times a week every other day during each 28 day cycle.'}, {'id': 'OG003', 'title': 'Part A: KPT-9274 40mg', 'description': 'Participants received 40mg of oral tablets of KPT-9274 three times a week every other day during each 28 day cycle.'}, {'id': 'OG004', 'title': 'Part A: KPT-9274 40mg BIW', 'description': 'Participants received KPT-9274 40mg of oral tablet biweekly (BIW) during each 28-day cycle.'}, {'id': 'OG005', 'title': 'Part B: KPT-9274 30mg + Niacin 500mg', 'description': 'Participants received KPT-9274 30mg of oral tablet along with a starting dose of 500mg niacin extended release (ER) orally three times a week every other day during each 28-day cycle.'}, {'id': 'OG006', 'title': 'Part B: KPT-9274 40mg + Niacin 500mg', 'description': 'Participants received KPT-9274 40mg of oral tablet along with a starting dose of 500mg niacin ER orally three times a week every other day during each 28-day cycle.'}, {'id': 'OG007', 'title': 'Part B: KPT-9274 60mg + Niacin 500mg', 'description': 'Participants received KPT-9274 60mg of oral tablet along with a starting dose of 500mg niacin ER orally three times a week every other day during each 28-day cycle.'}, {'id': 'OG008', 'title': 'Part B: KPT-9274 80mg + Niacin 500mg', 'description': 'Participants received KPT-9274 80mg of oral tablet along with a starting dose of 500mg niacin ER orally three times a week every other day during each 28-day cycle.'}, {'id': 'OG009', 'title': 'Part B: KPT-9274 100mg + Niacin 500mg', 'description': 'Participants received KPT-9274 100mg of oral tablet along with a starting dose of 500mg niacin ER orally three times a week every other day during each 28-day cycle.'}, {'id': 'OG010', 'title': 'Part C: KPT-9274 20mg + Nivolumab 480mg', 'description': 'Participants received KPT-9274 20mg of oral tablet three times a week every other day during each 28-day cycle along with 480mg of nivolumab intravenous infusion on Day 1 of each cycle (once every 4-week cycle).'}, {'id': 'OG011', 'title': 'Part C: KPT-9274 30mg + Nivolumab 480mg', 'description': 'Participants received KPT-9274 30mg of oral tablet three times a week every other day during each 28-day cycle along with 480mg of nivolumab intravenous infusion on Day 1 of each cycle (once every 4-week cycle).'}, {'id': 'OG012', 'title': 'Part C: KPT-9274 40mg + Nivolumab 480mg', 'description': 'Participants received KPT-9274 40mg of oral tablet three times a week every other day during each 28-day cycle along with 480mg of nivolumab intravenous infusion on Day 1 of each cycle (once every 4-week cycle).'}], 'classes': [{'categories': [{'measurements': [{'value': 'NA', 'comment': 'MTD was not determined based on insufficient number of participants with events.', 'groupId': 'OG000'}, {'value': 'NA', 'comment': 'MTD was not determined based on insufficient number of participants with events.', 'groupId': 'OG001'}, {'value': 'NA', 'comment': 'MTD was not determined based on insufficient number of participants with events.', 'groupId': 'OG002'}, {'value': 'NA', 'comment': 'MTD was not determined based on insufficient number of participants with events.', 'groupId': 'OG003'}, {'value': 'NA', 'comment': 'MTD was not determined based on insufficient number of participants with events.', 'groupId': 'OG004'}, {'value': 'NA', 'comment': 'MTD was not determined based on insufficient number of participants with events.', 'groupId': 'OG005'}, {'value': 'NA', 'comment': 'MTD was not determined based on insufficient number of participants with events.', 'groupId': 'OG006'}, {'value': 'NA', 'comment': 'MTD was not determined based on insufficient number of participants with events.', 'groupId': 'OG007'}, {'value': 'NA', 'comment': 'MTD was not determined based on insufficient number of participants with events.', 'groupId': 'OG008'}, {'value': 'NA', 'comment': 'MTD was not determined based on insufficient number of participants with events.', 'groupId': 'OG009'}, {'value': 'NA', 'comment': 'MTD was not determined based on insufficient number of participants with events.', 'groupId': 'OG010'}, {'value': 'NA', 'comment': 'MTD was not determined based on insufficient number of participants with events.', 'groupId': 'OG011'}, {'value': 'NA', 'comment': 'MTD was not determined based on insufficient number of participants with events.', 'groupId': 'OG012'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'From start of study drug administration up to 44 weeks', 'description': 'The MTD was defined as the highest dose at which less than or equal to (\\<=) 1 participant experienced a dose limiting toxicity (DLT) in Cycle 1. A DLT was defined as an adverse event (AE) or abnormal laboratory value occurring within the first 28 days of treatment of KPT-9274, excluding those clearly caused by underlying disease, disease progression, or external factors.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Study was terminated prematurely due to a lack of efficacy. Therefore, the data were not determined due to insufficient number of participants with events.'}, {'type': 'PRIMARY', 'title': 'Number of Dose Limiting Toxicities (DLT) Experienced by Participants', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}, {'value': '3', 'groupId': 'OG001'}, {'value': '5', 'groupId': 'OG002'}, {'value': '7', 'groupId': 'OG003'}, {'value': '5', 'groupId': 'OG004'}, {'value': '3', 'groupId': 'OG005'}, {'value': '4', 'groupId': 'OG006'}, {'value': '12', 'groupId': 'OG007'}, {'value': '7', 'groupId': 'OG008'}, {'value': '1', 'groupId': 'OG009'}, {'value': '1', 'groupId': 'OG010'}, {'value': '5', 'groupId': 'OG011'}, {'value': '4', 'groupId': 'OG012'}]}], 'groups': [{'id': 'OG000', 'title': 'Part A: KPT-9274 10mg', 'description': 'Participants received 10 milligrams (mg) of oral tablets of KPT-9274 three times a week every other day during each 28 day cycle.'}, {'id': 'OG001', 'title': 'Part A: KPT-9274 20mg', 'description': 'Participants received 20mg of oral tablets of KPT-9274 three times a week every other day during each 28 day cycle.'}, {'id': 'OG002', 'title': 'Part A: KPT-9274 30mg', 'description': 'Participants received 30mg of oral tablets of KPT-9274 three times a week every other day during each 28 day cycle.'}, {'id': 'OG003', 'title': 'Part A: KPT-9274 40mg', 'description': 'Participants received 40mg of oral tablets of KPT-9274 three times a week every other day during each 28 day cycle.'}, {'id': 'OG004', 'title': 'Part A: KPT-9274 40mg BIW', 'description': 'Participants received KPT-9274 40mg of oral tablet biweekly (BIW) during each 28-day cycle.'}, {'id': 'OG005', 'title': 'Part B: KPT-9274 30mg + Niacin 500mg', 'description': 'Participants received KPT-9274 30mg of oral tablet along with a starting dose of 500mg niacin extended release (ER) orally three times a week every other day during each 28-day cycle.'}, {'id': 'OG006', 'title': 'Part B: KPT-9274 40mg + Niacin 500mg', 'description': 'Participants received KPT-9274 40mg of oral tablet along with a starting dose of 500mg niacin ER orally three times a week every other day during each 28-day cycle.'}, {'id': 'OG007', 'title': 'Part B: KPT-9274 60mg + Niacin 500mg', 'description': 'Participants received KPT-9274 60mg of oral tablet along with a starting dose of 500mg niacin ER orally three times a week every other day during each 28-day cycle.'}, {'id': 'OG008', 'title': 'Part B: KPT-9274 80mg + Niacin 500mg', 'description': 'Participants received KPT-9274 80mg of oral tablet along with a starting dose of 500mg niacin ER orally three times a week every other day during each 28-day cycle.'}, {'id': 'OG009', 'title': 'Part B: KPT-9274 100mg + Niacin 500mg', 'description': 'Participants received KPT-9274 100mg of oral tablet along with a starting dose of 500mg niacin ER orally three times a week every other day during each 28-day cycle.'}, {'id': 'OG010', 'title': 'Part C: KPT-9274 20mg + Nivolumab 480mg', 'description': 'Participants received KPT-9274 20mg of oral tablet three times a week every other day during each 28-day cycle along with 480mg of nivolumab intravenous infusion on Day 1 of each cycle (once every 4-week cycle).'}, {'id': 'OG011', 'title': 'Part C: KPT-9274 30mg + Nivolumab 480mg', 'description': 'Participants received KPT-9274 30mg of oral tablet three times a week every other day during each 28-day cycle along with 480mg of nivolumab intravenous infusion on Day 1 of each cycle (once every 4-week cycle).'}, {'id': 'OG012', 'title': 'Part C: KPT-9274 40mg + Nivolumab 480mg', 'description': 'Participants received KPT-9274 40mg of oral tablet three times a week every other day during each 28-day cycle along with 480mg of nivolumab intravenous infusion on Day 1 of each cycle (once every 4-week cycle).'}], 'classes': [{'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '1', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}, {'value': '2', 'groupId': 'OG008'}, {'value': '0', 'groupId': 'OG009'}, {'value': '0', 'groupId': 'OG010'}, {'value': '0', 'groupId': 'OG011'}, {'value': '0', 'groupId': 'OG012'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'At Cycle 1 only (28-day cycle)', 'description': 'A DLT was defined as an AE or abnormal laboratory value occurring within the first 28 days of KPT-9274 treatment, excluding those clearly caused by underlying disease, disease progression, or extraneous causes, and meets any of the criteria for defining dose limiting toxicities.', 'unitOfMeasure': 'Number of DLTs', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population consisted of all participants who had received at least 1 dose of the study treatment.'}, {'type': 'PRIMARY', 'title': 'Number of Participants With Adverse Event (AE) of Severity Grade >= 3 or 4, Serious AEs, and AEs Leading to Treatment Discontinuation', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}, {'value': '3', 'groupId': 'OG001'}, {'value': '5', 'groupId': 'OG002'}, {'value': '7', 'groupId': 'OG003'}, {'value': '5', 'groupId': 'OG004'}, {'value': '3', 'groupId': 'OG005'}, {'value': '4', 'groupId': 'OG006'}, {'value': '12', 'groupId': 'OG007'}, {'value': '7', 'groupId': 'OG008'}, {'value': '1', 'groupId': 'OG009'}, {'value': '1', 'groupId': 'OG010'}, {'value': '5', 'groupId': 'OG011'}, {'value': '4', 'groupId': 'OG012'}]}], 'groups': [{'id': 'OG000', 'title': 'Part A: KPT-9274 10mg', 'description': 'Participants received 10mg of oral tablets of KPT-9274 three times a week every other day during each 28 day cycle.'}, {'id': 'OG001', 'title': 'Part A: KPT-9274 20mg', 'description': 'Participants received 20mg of oral tablets of KPT-9274 three times a week every other day during each 28 day cycle.'}, {'id': 'OG002', 'title': 'Part A: KPT-9274 30mg', 'description': 'Participants received 30mg of oral tablets of KPT-9274 three times a week every other day during each 28 day cycle.'}, {'id': 'OG003', 'title': 'Part A: KPT-9274 40mg', 'description': 'Participants received 40mg of oral tablets of KPT-9274 three times a week every other day during each 28 day cycle.'}, {'id': 'OG004', 'title': 'Part A: KPT-9274 40mg BIW', 'description': 'Participants received KPT-9274 40mg of oral tablet biweekly (BIW) during each 28-day cycle.'}, {'id': 'OG005', 'title': 'Part B: KPT-9274 30mg + Niacin 500mg', 'description': 'Participants received KPT-9274 30mg of oral tablet along with a starting dose of 500mg niacin extended release (ER) orally three times a week every other day during each 28-day cycle.'}, {'id': 'OG006', 'title': 'Part B: KPT-9274 40mg + Niacin 500mg', 'description': 'Participants received KPT-9274 40mg of oral tablet along with a starting dose of 500mg niacin ER orally three times a week every other day during each 28-day cycle.'}, {'id': 'OG007', 'title': 'Part B: KPT-9274 60mg + Niacin 500mg', 'description': 'Participants received KPT-9274 60mg of oral tablet along with a starting dose of 500mg niacin ER orally three times a week every other day during each 28-day cycle.'}, {'id': 'OG008', 'title': 'Part B: KPT-9274 80mg + Niacin 500mg', 'description': 'Participants received KPT-9274 80mg of oral tablet along with a starting dose of 500mg niacin ER orally three times a week every other day during each 28-day cycle.'}, {'id': 'OG009', 'title': 'Part B: KPT-9274 100mg + Niacin 500mg', 'description': 'Participants received KPT-9274 100mg of oral tablet along with a starting dose of 500mg niacin ER orally three times a week every other day during each 28-day cycle.'}, {'id': 'OG010', 'title': 'Part C: KPT-9274 20mg + Nivolumab 480mg', 'description': 'Participants received KPT-9274 20mg of oral tablet three times a week every other day during each 28-day cycle along with 480mg of nivolumab intravenous infusion on Day 1 of each cycle (once every 4-week cycle).'}, {'id': 'OG011', 'title': 'Part C: KPT-9274 30mg + Nivolumab 480mg', 'description': 'Participants received KPT-9274 30mg of oral tablet three times a week every other day during each 28-day cycle along with 480mg of nivolumab intravenous infusion on Day 1 of each cycle (once every 4-week cycle).'}, {'id': 'OG012', 'title': 'Part C: KPT-9274 40mg + Nivolumab 480mg', 'description': 'Participants received KPT-9274 40mg of oral tablet three times a week every other day during each 28-day cycle along with 480mg of nivolumab intravenous infusion on Day 1 of each cycle (once every 4-week cycle).'}], 'classes': [{'title': 'Maximum Grade 3/4 AEs', 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '2', 'groupId': 'OG001'}, {'value': '5', 'groupId': 'OG002'}, {'value': '7', 'groupId': 'OG003'}, {'value': '3', 'groupId': 'OG004'}, {'value': '2', 'groupId': 'OG005'}, {'value': '3', 'groupId': 'OG006'}, {'value': '10', 'groupId': 'OG007'}, {'value': '7', 'groupId': 'OG008'}, {'value': '1', 'groupId': 'OG009'}, {'value': '1', 'groupId': 'OG010'}, {'value': '4', 'groupId': 'OG011'}, {'value': '3', 'groupId': 'OG012'}]}]}, {'title': 'Maximum Grade 4 AEs', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '1', 'groupId': 'OG002'}, {'value': '3', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '1', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}, {'value': '0', 'groupId': 'OG008'}, {'value': '1', 'groupId': 'OG009'}, {'value': '0', 'groupId': 'OG010'}, {'value': '0', 'groupId': 'OG011'}, {'value': '1', 'groupId': 'OG012'}]}]}, {'title': 'Serious AEs', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '2', 'groupId': 'OG001'}, {'value': '2', 'groupId': 'OG002'}, {'value': '3', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '1', 'groupId': 'OG005'}, {'value': '1', 'groupId': 'OG006'}, {'value': '6', 'groupId': 'OG007'}, {'value': '1', 'groupId': 'OG008'}, {'value': '1', 'groupId': 'OG009'}, {'value': '1', 'groupId': 'OG010'}, {'value': '2', 'groupId': 'OG011'}, {'value': '2', 'groupId': 'OG012'}]}]}, {'title': 'AEs Leading to Study Treatment Discontinuation', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '1', 'groupId': 'OG002'}, {'value': '2', 'groupId': 'OG003'}, {'value': '1', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '1', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}, {'value': '2', 'groupId': 'OG008'}, {'value': '0', 'groupId': 'OG009'}, {'value': '0', 'groupId': 'OG010'}, {'value': '0', 'groupId': 'OG011'}, {'value': '1', 'groupId': 'OG012'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'From start of study drug administration up to 49 weeks', 'description': 'The AE severity was graded on a scale from 1 to 4 using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.03; any events not specifically listed in the scale were defined as: Grade 1 is mild; Grade 2 is moderate; Grade 3 is severe or medically significant; Grade 4 is life-threatening. An SAE was any untoward medical occurrence that at any dose met one, more of the following criteria: results in death, life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent, significant disability/incapacity, a congenital abnormality/birth defect, an important medical event. The AE leading to treatment discontinuation in the study.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population consisted of all participants who had received at least 1 dose of the study treatment.'}, {'type': 'PRIMARY', 'title': 'Percentage of Participants With Overall Response Rate (ORR)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}, {'value': '0', 'groupId': 'OG008'}, {'value': '0', 'groupId': 'OG009'}, {'value': '0', 'groupId': 'OG010'}, {'value': '0', 'groupId': 'OG011'}, {'value': '0', 'groupId': 'OG012'}]}], 'groups': [{'id': 'OG000', 'title': 'Part A: KPT-9274 10mg', 'description': 'Participants received 10mg of oral tablets of KPT-9274 three times a week every other day during each 28 day cycle.'}, {'id': 'OG001', 'title': 'Part A: KPT-9274 20mg', 'description': 'Participants received 20mg of oral tablets of KPT-9274 three times a week every other day during each 28 day cycle.'}, {'id': 'OG002', 'title': 'Part A: KPT-9274 30mg', 'description': 'Participants received 30mg of oral tablets of KPT-9274 three times a week every other day during each 28 day cycle.'}, {'id': 'OG003', 'title': 'Part A: KPT-9274 40mg', 'description': 'Participants received 40mg of oral tablets of KPT-9274 three times a week every other day during each 28 day cycle.'}, {'id': 'OG004', 'title': 'Part A: KPT-9274 40mg BIW', 'description': 'Participants received KPT-9274 40mg of oral tablet biweekly (BIW) during each 28-day cycle.'}, {'id': 'OG005', 'title': 'Part B: KPT-9274 30mg + Niacin 500mg', 'description': 'Participants received KPT-9274 30mg of oral tablet along with a starting dose of 500mg niacin extended release (ER) orally three times a week every other day during each 28-day cycle.'}, {'id': 'OG006', 'title': 'Part B: KPT-9274 40mg + Niacin 500mg', 'description': 'Participants received KPT-9274 40mg of oral tablet along with a starting dose of 500mg niacin ER orally three times a week every other day during each 28-day cycle.'}, {'id': 'OG007', 'title': 'Part B: KPT-9274 60mg + Niacin 500mg', 'description': 'Participants received KPT-9274 60mg of oral tablet along with a starting dose of 500mg niacin ER orally three times a week every other day during each 28-day cycle.'}, {'id': 'OG008', 'title': 'Part B: KPT-9274 80mg + Niacin 500mg', 'description': 'Participants received KPT-9274 80mg of oral tablet along with a starting dose of 500mg niacin ER orally three times a week every other day during each 28-day cycle.'}, {'id': 'OG009', 'title': 'Part B: KPT-9274 100mg + Niacin 500mg', 'description': 'Participants received KPT-9274 100mg of oral tablet along with a starting dose of 500mg niacin ER orally three times a week every other day during each 28-day cycle.'}, {'id': 'OG010', 'title': 'Part C: KPT-9274 20mg + Nivolumab 480mg', 'description': 'Participants received KPT-9274 20mg of oral tablet three times a week every other day during each 28-day cycle along with 480mg of nivolumab intravenous infusion on Day 1 of each cycle (once every 4-week cycle).'}, {'id': 'OG011', 'title': 'Part C: KPT-9274 30mg + Nivolumab 480mg', 'description': 'Participants received KPT-9274 30mg of oral tablet three times a week every other day during each 28-day cycle along with 480mg of nivolumab intravenous infusion on Day 1 of each cycle (once every 4-week cycle).'}, {'id': 'OG012', 'title': 'Part C: KPT-9274 40mg + Nivolumab 480mg', 'description': 'Participants received KPT-9274 40mg of oral tablet three times a week every other day during each 28-day cycle along with 480mg of nivolumab intravenous infusion on Day 1 of each cycle (once every 4-week cycle).'}], 'timeFrame': 'From date of randomization up to 44 weeks', 'description': 'The ORR was defined as percentage of participants who had a response of partial response (PR) or complete response (CR). The PR was achieved when a participant had at least a 30 percent (%) decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. The CR was achieved in a participant when all target lesions disappeared. Any pathological lymph nodes (whether target or non target) must have reduction in the short axis to \\<10 millimeter (mm).', 'reportingStatus': 'POSTED', 'populationDescription': 'Study was terminated prematurely due to a lack of efficacy during primary analysis stage. Data for this outcome measure was not collected or analyzed as per planned analysis.'}, {'type': 'PRIMARY', 'title': 'Percentage of Participants With Disease Control Rate (DCR)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}, {'value': '0', 'groupId': 'OG008'}, {'value': '0', 'groupId': 'OG009'}, {'value': '0', 'groupId': 'OG010'}, {'value': '0', 'groupId': 'OG011'}, {'value': '0', 'groupId': 'OG012'}]}], 'groups': [{'id': 'OG000', 'title': 'Part A: KPT-9274 10mg', 'description': 'Participants received 10mg of oral tablets of KPT-9274 three times a week every other day during each 28 day cycle.'}, {'id': 'OG001', 'title': 'Part A: KPT-9274 20mg', 'description': 'Participants received 20mg of oral tablets of KPT-9274 three times a week every other day during each 28 day cycle.'}, {'id': 'OG002', 'title': 'Part A: KPT-9274 30mg', 'description': 'Participants received 30mg of oral tablets of KPT-9274 three times a week every other day during each 28 day cycle.'}, {'id': 'OG003', 'title': 'Part A: KPT-9274 40mg', 'description': 'Participants received 40mg of oral tablets of KPT-9274 three times a week every other day during each 28 day cycle.'}, {'id': 'OG004', 'title': 'Part A: KPT-9274 40mg BIW', 'description': 'Participants received KPT-9274 40mg of oral tablet biweekly (BIW) during each 28-day cycle.'}, {'id': 'OG005', 'title': 'Part B: KPT-9274 30mg + Niacin 500mg', 'description': 'Participants received KPT-9274 30mg of oral tablet along with a starting dose of 500mg niacin extended release (ER) orally three times a week every other day during each 28-day cycle.'}, {'id': 'OG006', 'title': 'Part B: KPT-9274 40mg + Niacin 500mg', 'description': 'Participants received KPT-9274 40mg of oral tablet along with a starting dose of 500mg niacin ER orally three times a week every other day during each 28-day cycle.'}, {'id': 'OG007', 'title': 'Part B: KPT-9274 60mg + Niacin 500mg', 'description': 'Participants received KPT-9274 60mg of oral tablet along with a starting dose of 500mg niacin ER orally three times a week every other day during each 28-day cycle.'}, {'id': 'OG008', 'title': 'Part B: KPT-9274 80mg + Niacin 500mg', 'description': 'Participants received KPT-9274 80mg of oral tablet along with a starting dose of 500mg niacin ER orally three times a week every other day during each 28-day cycle.'}, {'id': 'OG009', 'title': 'Part B: KPT-9274 100mg + Niacin 500mg', 'description': 'Participants received KPT-9274 100mg of oral tablet along with a starting dose of 500mg niacin ER orally three times a week every other day during each 28-day cycle.'}, {'id': 'OG010', 'title': 'Part C: KPT-9274 20mg + Nivolumab 480mg', 'description': 'Participants received KPT-9274 20mg of oral tablet three times a week every other day during each 28-day cycle along with 480mg of nivolumab intravenous infusion on Day 1 of each cycle (once every 4-week cycle).'}, {'id': 'OG011', 'title': 'Part C: KPT-9274 30mg + Nivolumab 480mg', 'description': 'Participants received KPT-9274 30mg of oral tablet three times a week every other day during each 28-day cycle along with 480mg of nivolumab intravenous infusion on Day 1 of each cycle (once every 4-week cycle).'}, {'id': 'OG012', 'title': 'Part C: KPT-9274 40mg + Nivolumab 480mg', 'description': 'Participants received KPT-9274 40mg of oral tablet three times a week every other day during each 28-day cycle along with 480mg of nivolumab intravenous infusion on Day 1 of each cycle (once every 4-week cycle).'}], 'timeFrame': 'From date of the first study treatment up to 44 weeks', 'description': 'The DCR was defined as percentage of participants who have a response of CR, PR, and stable disease (SD) \\>= 16 weeks, DCR = CR + PR+ SD. The PR was achieved when a participant had at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. The CR was achieved in a participant when all target lesions disappeared. Any pathological lymph nodes (whether target or non-target) must have reduction in the short axis to \\<10mm. The SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD).', 'reportingStatus': 'POSTED', 'populationDescription': 'Study was terminated prematurely due to a lack of efficacy during primary analysis stage. Data for this outcome measure was not collected or analyzed as per planned analysis.'}, {'type': 'PRIMARY', 'title': 'Progression-free Survival (PFS)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}, {'value': '0', 'groupId': 'OG008'}, {'value': '0', 'groupId': 'OG009'}, {'value': '0', 'groupId': 'OG010'}, {'value': '0', 'groupId': 'OG011'}, {'value': '0', 'groupId': 'OG012'}]}], 'groups': [{'id': 'OG000', 'title': 'Part A: KPT-9274 10mg', 'description': 'Participants received 10mg of oral tablets of KPT-9274 three times a week every other day during each 28 day cycle.'}, {'id': 'OG001', 'title': 'Part A: KPT-9274 20mg', 'description': 'Participants received 20mg of oral tablets of KPT-9274 three times a week every other day during each 28 day cycle.'}, {'id': 'OG002', 'title': 'Part A: KPT-9274 30mg', 'description': 'Participants received 30mg of oral tablets of KPT-9274 three times a week every other day during each 28 day cycle.'}, {'id': 'OG003', 'title': 'Part A: KPT-9274 40mg', 'description': 'Participants received 40mg of oral tablets of KPT-9274 three times a week every other day during each 28 day cycle.'}, {'id': 'OG004', 'title': 'Part A: KPT-9274 40mg BIW', 'description': 'Participants received KPT-9274 40mg of oral tablet biweekly (BIW) during each 28-day cycle.'}, {'id': 'OG005', 'title': 'Part B: KPT-9274 30mg + Niacin 500mg', 'description': 'Participants received KPT-9274 30mg of oral tablet along with a starting dose of 500mg niacin extended release (ER) orally three times a week every other day during each 28-day cycle.'}, {'id': 'OG006', 'title': 'Part B: KPT-9274 40mg + Niacin 500mg', 'description': 'Participants received KPT-9274 40mg of oral tablet along with a starting dose of 500mg niacin ER orally three times a week every other day during each 28-day cycle.'}, {'id': 'OG007', 'title': 'Part B: KPT-9274 60mg + Niacin 500mg', 'description': 'Participants received KPT-9274 60mg of oral tablet along with a starting dose of 500mg niacin ER orally three times a week every other day during each 28-day cycle.'}, {'id': 'OG008', 'title': 'Part B: KPT-9274 80mg + Niacin 500mg', 'description': 'Participants received KPT-9274 80mg of oral tablet along with a starting dose of 500mg niacin ER orally three times a week every other day during each 28-day cycle.'}, {'id': 'OG009', 'title': 'Part B: KPT-9274 100mg + Niacin 500mg', 'description': 'Participants received KPT-9274 100mg of oral tablet along with a starting dose of 500mg niacin ER orally three times a week every other day during each 28-day cycle.'}, {'id': 'OG010', 'title': 'Part C: KPT-9274 20mg + Nivolumab 480mg', 'description': 'Participants received KPT-9274 20mg of oral tablet three times a week every other day during each 28-day cycle along with 480mg of nivolumab intravenous infusion on Day 1 of each cycle (once every 4-week cycle).'}, {'id': 'OG011', 'title': 'Part C: KPT-9274 30mg + Nivolumab 480mg', 'description': 'Participants received KPT-9274 30mg of oral tablet three times a week every other day during each 28-day cycle along with 480mg of nivolumab intravenous infusion on Day 1 of each cycle (once every 4-week cycle).'}, {'id': 'OG012', 'title': 'Part C: KPT-9274 40mg + Nivolumab 480mg', 'description': 'Participants received KPT-9274 40mg of oral tablet three times a week every other day during each 28-day cycle along with 480mg of nivolumab intravenous infusion on Day 1 of each cycle (once every 4-week cycle).'}], 'timeFrame': 'From the date of first study treatment until the first date of PD, or death due (up to 44 weeks)', 'description': 'The PFS was defined as the duration of time from date of the first study treatment until the first date that PD is objectively documented or death due to any cause. The PD is defined as at least a 20% increase in the sum of diameters of measured lesions taking as references the smallest sum of diameters recorded since the treatment started. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5mm. Appearance of one or more new lesions will also constitute PD.', 'reportingStatus': 'POSTED', 'populationDescription': 'Study was terminated prematurely due to a lack of efficacy during primary analysis stage. Data for this outcome measure was not collected or analyzed as per planned analysis.'}, {'type': 'PRIMARY', 'title': 'Overall Survival (OS)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}, {'value': '0', 'groupId': 'OG008'}, {'value': '0', 'groupId': 'OG009'}, {'value': '0', 'groupId': 'OG010'}, {'value': '0', 'groupId': 'OG011'}, {'value': '0', 'groupId': 'OG012'}]}], 'groups': [{'id': 'OG000', 'title': 'Part A: KPT-9274 10mg', 'description': 'Participants received 10mg of oral tablets of KPT-9274 three times a week every other day during each 28 day cycle.'}, {'id': 'OG001', 'title': 'Part A: KPT-9274 20mg', 'description': 'Participants received 20mg of oral tablets of KPT-9274 three times a week every other day during each 28 day cycle.'}, {'id': 'OG002', 'title': 'Part A: KPT-9274 30mg', 'description': 'Participants received 30mg of oral tablets of KPT-9274 three times a week every other day during each 28 day cycle.'}, {'id': 'OG003', 'title': 'Part A: KPT-9274 40mg', 'description': 'Participants received 40mg of oral tablets of KPT-9274 three times a week every other day during each 28 day cycle.'}, {'id': 'OG004', 'title': 'Part A: KPT-9274 40mg BIW', 'description': 'Participants received KPT-9274 40mg of oral tablet biweekly (BIW) during each 28-day cycle.'}, {'id': 'OG005', 'title': 'Part B: KPT-9274 30mg + Niacin 500mg', 'description': 'Participants received KPT-9274 30mg of oral tablet along with a starting dose of 500mg niacin extended release (ER) orally three times a week every other day during each 28-day cycle.'}, {'id': 'OG006', 'title': 'Part B: KPT-9274 40mg + Niacin 500mg', 'description': 'Participants received KPT-9274 40mg of oral tablet along with a starting dose of 500mg niacin ER orally three times a week every other day during each 28-day cycle.'}, {'id': 'OG007', 'title': 'Part B: KPT-9274 60mg + Niacin 500mg', 'description': 'Participants received KPT-9274 60mg of oral tablet along with a starting dose of 500mg niacin ER orally three times a week every other day during each 28-day cycle.'}, {'id': 'OG008', 'title': 'Part B: KPT-9274 80mg + Niacin 500mg', 'description': 'Participants received KPT-9274 80mg of oral tablet along with a starting dose of 500mg niacin ER orally three times a week every other day during each 28-day cycle.'}, {'id': 'OG009', 'title': 'Part B: KPT-9274 100mg + Niacin 500mg', 'description': 'Participants received KPT-9274 100mg of oral tablet along with a starting dose of 500mg niacin ER orally three times a week every other day during each 28-day cycle.'}, {'id': 'OG010', 'title': 'Part C: KPT-9274 20mg + Nivolumab 480mg', 'description': 'Participants received KPT-9274 20mg of oral tablet three times a week every other day during each 28-day cycle along with 480mg of nivolumab intravenous infusion on Day 1 of each cycle (once every 4-week cycle).'}, {'id': 'OG011', 'title': 'Part C: KPT-9274 30mg + Nivolumab 480mg', 'description': 'Participants received KPT-9274 30mg of oral tablet three times a week every other day during each 28-day cycle along with 480mg of nivolumab intravenous infusion on Day 1 of each cycle (once every 4-week cycle).'}, {'id': 'OG012', 'title': 'Part C: KPT-9274 40mg + Nivolumab 480mg', 'description': 'Participants received KPT-9274 40mg of oral tablet three times a week every other day during each 28-day cycle along with 480mg of nivolumab intravenous infusion on Day 1 of each cycle (once every 4-week cycle).'}], 'timeFrame': 'From date of the first study treatment until death (up to 44 weeks)', 'description': 'The OS was defined as the duration of time from date of the first study treatment until death from any cause.', 'reportingStatus': 'POSTED', 'populationDescription': 'Study was terminated prematurely due to a lack of efficacy during primary analysis stage. Data for this outcome measure was not collected or analyzed as per planned analysis.'}, {'type': 'PRIMARY', 'title': 'Time to Progression (TTP)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}, {'value': '0', 'groupId': 'OG008'}, {'value': '0', 'groupId': 'OG009'}, {'value': '0', 'groupId': 'OG010'}, {'value': '0', 'groupId': 'OG011'}, {'value': '0', 'groupId': 'OG012'}]}], 'groups': [{'id': 'OG000', 'title': 'Part A: KPT-9274 10mg', 'description': 'Participants received 10mg of oral tablets of KPT-9274 three times a week every other day during each 28 day cycle.'}, {'id': 'OG001', 'title': 'Part A: KPT-9274 20mg', 'description': 'Participants received 20mg of oral tablets of KPT-9274 three times a week every other day during each 28 day cycle.'}, {'id': 'OG002', 'title': 'Part A: KPT-9274 30mg', 'description': 'Participants received 30mg of oral tablets of KPT-9274 three times a week every other day during each 28 day cycle.'}, {'id': 'OG003', 'title': 'Part A: KPT-9274 40mg', 'description': 'Participants received 40mg of oral tablets of KPT-9274 three times a week every other day during each 28 day cycle.'}, {'id': 'OG004', 'title': 'Part A: KPT-9274 40mg BIW', 'description': 'Participants received KPT-9274 40mg of oral tablet biweekly (BIW) during each 28-day cycle.'}, {'id': 'OG005', 'title': 'Part B: KPT-9274 30mg + Niacin 500mg', 'description': 'Participants received KPT-9274 30mg of oral tablet along with a starting dose of 500mg niacin extended release (ER) orally three times a week every other day during each 28-day cycle.'}, {'id': 'OG006', 'title': 'Part B: KPT-9274 40mg + Niacin 500mg', 'description': 'Participants received KPT-9274 40mg of oral tablet along with a starting dose of 500mg niacin ER orally three times a week every other day during each 28-day cycle.'}, {'id': 'OG007', 'title': 'Part B: KPT-9274 60mg + Niacin 500mg', 'description': 'Participants received KPT-9274 60mg of oral tablet along with a starting dose of 500mg niacin ER orally three times a week every other day during each 28-day cycle.'}, {'id': 'OG008', 'title': 'Part B: KPT-9274 80mg + Niacin 500mg', 'description': 'Participants received KPT-9274 80mg of oral tablet along with a starting dose of 500mg niacin ER orally three times a week every other day during each 28-day cycle.'}, {'id': 'OG009', 'title': 'Part B: KPT-9274 100mg + Niacin 500mg', 'description': 'Participants received KPT-9274 100mg of oral tablet along with a starting dose of 500mg niacin ER orally three times a week every other day during each 28-day cycle.'}, {'id': 'OG010', 'title': 'Part C: KPT-9274 20mg + Nivolumab 480mg', 'description': 'Participants received KPT-9274 20mg of oral tablet three times a week every other day during each 28-day cycle along with 480mg of nivolumab intravenous infusion on Day 1 of each cycle (once every 4-week cycle).'}, {'id': 'OG011', 'title': 'Part C: KPT-9274 30mg + Nivolumab 480mg', 'description': 'Participants received KPT-9274 30mg of oral tablet three times a week every other day during each 28-day cycle along with 480mg of nivolumab intravenous infusion on Day 1 of each cycle (once every 4-week cycle).'}, {'id': 'OG012', 'title': 'Part C: KPT-9274 40mg + Nivolumab 480mg', 'description': 'Participants received KPT-9274 40mg of oral tablet three times a week every other day during each 28-day cycle along with 480mg of nivolumab intravenous infusion on Day 1 of each cycle (once every 4-week cycle).'}], 'timeFrame': 'From date of the first study treatment until the first date of PD or death (up to 44 weeks)', 'description': 'The TTP was defined as the duration of time from date of the first study treatment until the first date that PD was objectively documented or death due to PD.', 'reportingStatus': 'POSTED', 'populationDescription': 'Study was terminated prematurely due to a lack of efficacy during primary analysis stage. Data for this outcome measure was not collected or analyzed as per planned analysis.'}, {'type': 'PRIMARY', 'title': 'Duration of Response (DOR)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}, {'value': '0', 'groupId': 'OG008'}, {'value': '0', 'groupId': 'OG009'}, {'value': '0', 'groupId': 'OG010'}, {'value': '0', 'groupId': 'OG011'}, {'value': '0', 'groupId': 'OG012'}]}], 'groups': [{'id': 'OG000', 'title': 'Part A: KPT-9274 10mg', 'description': 'Participants received 10mg of oral tablets of KPT-9274 three times a week every other day during each 28 day cycle.'}, {'id': 'OG001', 'title': 'Part A: KPT-9274 20mg', 'description': 'Participants received 20mg of oral tablets of KPT-9274 three times a week every other day during each 28 day cycle.'}, {'id': 'OG002', 'title': 'Part A: KPT-9274 30mg', 'description': 'Participants received 30mg of oral tablets of KPT-9274 three times a week every other day during each 28 day cycle.'}, {'id': 'OG003', 'title': 'Part A: KPT-9274 40mg', 'description': 'Participants received 40mg of oral tablets of KPT-9274 three times a week every other day during each 28 day cycle.'}, {'id': 'OG004', 'title': 'Part A: KPT-9274 40mg BIW', 'description': 'Participants received KPT-9274 40mg of oral tablet biweekly (BIW) during each 28-day cycle.'}, {'id': 'OG005', 'title': 'Part B: KPT-9274 30mg + Niacin 500mg', 'description': 'Participants received KPT-9274 30mg of oral tablet along with a starting dose of 500mg niacin extended release (ER) orally three times a week every other day during each 28-day cycle.'}, {'id': 'OG006', 'title': 'Part B: KPT-9274 40mg + Niacin 500mg', 'description': 'Participants received KPT-9274 40mg of oral tablet along with a starting dose of 500mg niacin ER orally three times a week every other day during each 28-day cycle.'}, {'id': 'OG007', 'title': 'Part B: KPT-9274 60mg + Niacin 500mg', 'description': 'Participants received KPT-9274 60mg of oral tablet along with a starting dose of 500mg niacin ER orally three times a week every other day during each 28-day cycle.'}, {'id': 'OG008', 'title': 'Part B: KPT-9274 80mg + Niacin 500mg', 'description': 'Participants received KPT-9274 80mg of oral tablet along with a starting dose of 500mg niacin ER orally three times a week every other day during each 28-day cycle.'}, {'id': 'OG009', 'title': 'Part B: KPT-9274 100mg + Niacin 500mg', 'description': 'Participants received KPT-9274 100mg of oral tablet along with a starting dose of 500mg niacin ER orally three times a week every other day during each 28-day cycle.'}, {'id': 'OG010', 'title': 'Part C: KPT-9274 20mg + Nivolumab 480mg', 'description': 'Participants received KPT-9274 20mg of oral tablet three times a week every other day during each 28-day cycle along with 480mg of nivolumab intravenous infusion on Day 1 of each cycle (once every 4-week cycle).'}, {'id': 'OG011', 'title': 'Part C: KPT-9274 30mg + Nivolumab 480mg', 'description': 'Participants received KPT-9274 30mg of oral tablet three times a week every other day during each 28-day cycle along with 480mg of nivolumab intravenous infusion on Day 1 of each cycle (once every 4-week cycle).'}, {'id': 'OG012', 'title': 'Part C: KPT-9274 40mg + Nivolumab 480mg', 'description': 'Participants received KPT-9274 40mg of oral tablet three times a week every other day during each 28-day cycle along with 480mg of nivolumab intravenous infusion on Day 1 of each cycle (once every 4-week cycle).'}], 'timeFrame': 'Up to 44 weeks', 'description': 'The DOR was defined as the duration of time from the first meeting CR or PR measurement criteria (whichever occurs first) until the first date diseases progression.', 'reportingStatus': 'POSTED', 'populationDescription': 'Study was terminated prematurely due to a lack of efficacy during primary analysis stage. Data for this outcome measure was not collected or analyzed as per planned analysis.'}, {'type': 'SECONDARY', 'title': 'Maximum Plasma Concentration (Cmax) in Participants Who Received KPT-9274', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}, {'value': '0', 'groupId': 'OG008'}, {'value': '0', 'groupId': 'OG009'}, {'value': '0', 'groupId': 'OG010'}, {'value': '0', 'groupId': 'OG011'}, {'value': '0', 'groupId': 'OG012'}]}], 'groups': [{'id': 'OG000', 'title': 'Part A: KPT-9274 10mg', 'description': 'Participants received 10mg of oral tablets of KPT-9274 three times a week every other day during each 28 day cycle.'}, {'id': 'OG001', 'title': 'Part A: KPT-9274 20mg', 'description': 'Participants received 20mg of oral tablets of KPT-9274 three times a week every other day during each 28 day cycle.'}, {'id': 'OG002', 'title': 'Part A: KPT-9274 30mg', 'description': 'Participants received 30mg of oral tablets of KPT-9274 three times a week every other day during each 28 day cycle.'}, {'id': 'OG003', 'title': 'Part A: KPT-9274 40mg', 'description': 'Participants received 40mg of oral tablets of KPT-9274 three times a week every other day during each 28 day cycle.'}, {'id': 'OG004', 'title': 'Part A: KPT-9274 40mg BIW', 'description': 'Participants received KPT-9274 20mg of oral tablet biweekly (BIW) during each 28-day cycle.'}, {'id': 'OG005', 'title': 'Part B: KPT-9274 30mg + Niacin 500mg', 'description': 'Participants received KPT-9274 30mg of oral tablet along with a starting dose of 500mg niacin extended release (ER) orally three times a week every other day during each 28-day cycle.'}, {'id': 'OG006', 'title': 'Part B: KPT-9274 40mg + Niacin 500mg', 'description': 'Participants received KPT-9274 40mg of oral tablet along with a starting dose of 500mg niacin ER orally three times a week every other day during each 28-day cycle.'}, {'id': 'OG007', 'title': 'Part B: KPT-9274 60mg + Niacin 500mg', 'description': 'Participants received KPT-9274 60mg of oral tablet along with a starting dose of 500mg niacin ER orally three times a week every other day during each 28-day cycle.'}, {'id': 'OG008', 'title': 'Part B: KPT-9274 80mg + Niacin 500mg', 'description': 'Participants received KPT-9274 80mg of oral tablet along with a starting dose of 500mg niacin ER orally three times a week every other day during each 28-day cycle.'}, {'id': 'OG009', 'title': 'Part B: KPT-9274 100mg + Niacin 500mg', 'description': 'Participants received KPT-9274 100mg of oral tablet along with a starting dose of 500mg niacin ER orally three times a week every other day during each 28-day cycle.'}, {'id': 'OG010', 'title': 'Part C: KPT-9274 20mg + Nivolumab 480mg', 'description': 'Participants received KPT-9274 20mg of oral tablet three times a week every other day during each 28-day cycle along with 480mg of nivolumab intravenous infusion on Day 1 of each cycle (once every 4-week cycle).'}, {'id': 'OG011', 'title': 'Part C: KPT-9274 30mg + Nivolumab 480mg', 'description': 'Participants received KPT-9274 30mg of oral tablet three times a week every other day during each 28-day cycle along with 480mg of nivolumab intravenous infusion on Day 1 of each cycle (once every 4-week cycle).'}, {'id': 'OG012', 'title': 'Part C: KPT-9274 40mg + Nivolumab 480mg', 'description': 'Participants received KPT-9274 40mg of oral tablet three times a week every other day during each 28-day cycle along with 480mg of nivolumab intravenous infusion on Day 1 of each cycle (once every 4-week cycle).'}], 'timeFrame': 'Cycle 1 and 2: Pre-dose, 3, 6, 8, 24, and 48 hours post-dose (each cycle =28 days)', 'description': 'Cmax achieved by the KPT-9274 after the first dose administrations.', 'reportingStatus': 'POSTED', 'populationDescription': 'Study was terminated prematurely due to a lack of efficacy during primary analysis stage. Data for this outcome measure was not collected or analyzed as per planned analysis.'}, {'type': 'SECONDARY', 'title': 'Time-to-peak Plasma Concentration (Tmax) in Participants Who Received KPT-9274', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}, {'value': '0', 'groupId': 'OG008'}, {'value': '0', 'groupId': 'OG009'}, {'value': '0', 'groupId': 'OG010'}, {'value': '0', 'groupId': 'OG011'}, {'value': '0', 'groupId': 'OG012'}]}], 'groups': [{'id': 'OG000', 'title': 'Part A: KPT-9274 10mg', 'description': 'Participants received 10mg of oral tablets of KPT-9274 three times a week every other day during each 28 day cycle.'}, {'id': 'OG001', 'title': 'Part A: KPT-9274 20mg', 'description': 'Participants received 20mg of oral tablets of KPT-9274 three times a week every other day during each 28 day cycle.'}, {'id': 'OG002', 'title': 'Part A: KPT-9274 30mg', 'description': 'Participants received 30mg of oral tablets of KPT-9274 three times a week every other day during each 28 day cycle.'}, {'id': 'OG003', 'title': 'Part A: KPT-9274 40mg', 'description': 'Participants received 40mg of oral tablets of KPT-9274 three times a week every other day during each 28 day cycle.'}, {'id': 'OG004', 'title': 'Part A: KPT-9274 40mg BIW', 'description': 'Participants received KPT-9274 40mg of oral tablet biweekly (BIW) during each 28-day cycle.'}, {'id': 'OG005', 'title': 'Part B: KPT-9274 30mg + Niacin 500mg', 'description': 'Participants received KPT-9274 30mg of oral tablet along with a starting dose of 500mg niacin extended release (ER) orally three times a week every other day during each 28-day cycle.'}, {'id': 'OG006', 'title': 'Part B: KPT-9274 40mg + Niacin 500mg', 'description': 'Participants received KPT-9274 40mg of oral tablet along with a starting dose of 500mg niacin ER orally three times a week every other day during each 28-day cycle.'}, {'id': 'OG007', 'title': 'Part B: KPT-9274 60mg + Niacin 500mg', 'description': 'Participants received KPT-9274 60mg of oral tablet along with a starting dose of 500mg niacin ER orally three times a week every other day during each 28-day cycle.'}, {'id': 'OG008', 'title': 'Part B: KPT-9274 80mg + Niacin 500mg', 'description': 'Participants received KPT-9274 80mg of oral tablet along with a starting dose of 500mg niacin ER orally three times a week every other day during each 28-day cycle.'}, {'id': 'OG009', 'title': 'Part B: KPT-9274 100mg + Niacin 500mg', 'description': 'Participants received KPT-9274 100mg of oral tablet along with a starting dose of 500mg niacin ER orally three times a week every other day during each 28-day cycle.'}, {'id': 'OG010', 'title': 'Part C: KPT-9274 20mg + Nivolumab 480mg', 'description': 'Participants received KPT-9274 20mg of oral tablet three times a week every other day during each 28-day cycle along with 480mg of nivolumab intravenous infusion on Day 1 of each cycle (once every 4-week cycle).'}, {'id': 'OG011', 'title': 'Part C: KPT-9274 30mg + Nivolumab 480mg', 'description': 'Participants received KPT-9274 30mg of oral tablet three times a week every other day during each 28-day cycle along with 480mg of nivolumab intravenous infusion on Day 1 of each cycle (once every 4-week cycle).'}, {'id': 'OG012', 'title': 'Part C: KPT-9274 40mg + Nivolumab 480mg', 'description': 'Participants received KPT-9274 40mg of oral tablet three times a week every other day during each 28-day cycle along with 480mg of nivolumab intravenous infusion on Day 1 of each cycle (once every 4-week cycle).'}], 'timeFrame': 'Cycle 1 and 2: Pre-dose, 3, 6, 8, 24, and 48 hours post-dose (each cycle =28 days)', 'description': 'Time taken by KPT-9274 to achieve maximum plasma concentration after the first dose administration.', 'reportingStatus': 'POSTED', 'populationDescription': 'Study was terminated prematurely due to a lack of efficacy during primary analysis stage. Data for this outcome measure was not collected or analyzed as per planned analysis.'}, {'type': 'SECONDARY', 'title': 'Terminal Half-life (T1/2) in Participants Who Received KPT-9274', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}, {'value': '0', 'groupId': 'OG008'}, {'value': '0', 'groupId': 'OG009'}, {'value': '0', 'groupId': 'OG010'}, {'value': '0', 'groupId': 'OG011'}, {'value': '0', 'groupId': 'OG012'}]}], 'groups': [{'id': 'OG000', 'title': 'Part A: KPT-9274 10mg', 'description': 'Participants received 10mg of oral tablets of KPT-9274 three times a week every other day during each 28 day cycle.'}, {'id': 'OG001', 'title': 'Part A: KPT-9274 20mg', 'description': 'Participants received 20mg of oral tablets of KPT-9274 three times a week every other day during each 28 day cycle.'}, {'id': 'OG002', 'title': 'Part A: KPT-9274 30mg', 'description': 'Participants received 30mg of oral tablets of KPT-9274 three times a week every other day during each 28 day cycle.'}, {'id': 'OG003', 'title': 'Part A: KPT-9274 40mg', 'description': 'Participants received 40mg of oral tablets of KPT-9274 three times a week every other day during each 28 day cycle.'}, {'id': 'OG004', 'title': 'Part A: KPT-9274 40mg BIW', 'description': 'Participants received KPT-9274 40mg of oral tablet biweekly (BIW) during each 28-day cycle.'}, {'id': 'OG005', 'title': 'Part B: KPT-9274 30mg + Niacin 500mg', 'description': 'Participants received KPT-9274 30mg of oral tablet along with a starting dose of 500mg niacin extended release (ER) orally three times a week every other day during each 28-day cycle.'}, {'id': 'OG006', 'title': 'Part B: KPT-9274 40mg + Niacin 500mg', 'description': 'Participants received KPT-9274 40mg of oral tablet along with a starting dose of 500mg niacin ER orally three times a week every other day during each 28-day cycle.'}, {'id': 'OG007', 'title': 'Part B: KPT-9274 60mg + Niacin 500mg', 'description': 'Participants received KPT-9274 60mg of oral tablet along with a starting dose of 500mg niacin ER orally three times a week every other day during each 28-day cycle.'}, {'id': 'OG008', 'title': 'Part B: KPT-9274 80mg + Niacin 500mg', 'description': 'Participants received KPT-9274 80mg of oral tablet along with a starting dose of 500mg niacin ER orally three times a week every other day during each 28-day cycle.'}, {'id': 'OG009', 'title': 'Part B: KPT-9274 100mg + Niacin 500mg', 'description': 'Participants received KPT-9274 100mg of oral tablet along with a starting dose of 500mg niacin ER orally three times a week every other day during each 28-day cycle.'}, {'id': 'OG010', 'title': 'Part C: KPT-9274 20mg + Nivolumab 480mg', 'description': 'Participants received KPT-9274 20mg of oral tablet three times a week every other day during each 28-day cycle along with 480mg of nivolumab intravenous infusion on Day 1 of each cycle (once every 4-week cycle).'}, {'id': 'OG011', 'title': 'Part C: KPT-9274 30mg + Nivolumab 480mg', 'description': 'Participants received KPT-9274 30mg of oral tablet three times a week every other day during each 28-day cycle along with 480mg of nivolumab intravenous infusion on Day 1 of each cycle (once every 4-week cycle).'}, {'id': 'OG012', 'title': 'Part C: KPT-9274 40mg + Nivolumab 480mg', 'description': 'Participants received KPT-9274 40mg of oral tablet three times a week every other day during each 28-day cycle along with 480mg of nivolumab intravenous infusion on Day 1 of each cycle (once every 4-week cycle).'}], 'timeFrame': 'Cycle 1 and 2: Pre-dose, 3, 6, 8, 24, and 48 hours post-dose (each cycle =28 days)', 'description': 'The T1/2 was defied as the time it takes for the concentration of KPT-9274 in the plasma to be reduced by 50%.', 'reportingStatus': 'POSTED', 'populationDescription': 'Study was terminated prematurely due to a lack of efficacy during primary analysis stage. Data for this outcome measure was not collected or analyzed as per planned analysis.'}, {'type': 'SECONDARY', 'title': 'Volume of Distribution (Vd/F) in Participants Who Received KPT-9274', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}, {'value': '0', 'groupId': 'OG008'}, {'value': '0', 'groupId': 'OG009'}, {'value': '0', 'groupId': 'OG010'}, {'value': '0', 'groupId': 'OG011'}, {'value': '0', 'groupId': 'OG012'}]}], 'groups': [{'id': 'OG000', 'title': 'Part A: KPT-9274 10mg', 'description': 'Participants received 10mg of oral tablets of KPT-9274 three times a week every other day during each 28 day cycle.'}, {'id': 'OG001', 'title': 'Part A: KPT-9274 20mg', 'description': 'Participants received 20mg of oral tablets of KPT-9274 three times a week every other day during each 28 day cycle.'}, {'id': 'OG002', 'title': 'Part A: KPT-9274 30mg', 'description': 'Participants received 30mg of oral tablets of KPT-9274 three times a week every other day during each 28 day cycle.'}, {'id': 'OG003', 'title': 'Part A: KPT-9274 40mg', 'description': 'Participants received 40mg of oral tablets of KPT-9274 three times a week every other day during each 28 day cycle.'}, {'id': 'OG004', 'title': 'Part A: KPT-9274 40mg BIW', 'description': 'Participants received KPT-9274 40mg of oral tablet biweekly (BIW) during each 28-day cycle.'}, {'id': 'OG005', 'title': 'Part B: KPT-9274 30mg + Niacin 500mg', 'description': 'Participants received KPT-9274 30mg of oral tablet along with a starting dose of 500mg niacin extended release (ER) orally three times a week every other day during each 28-day cycle.'}, {'id': 'OG006', 'title': 'Part B: KPT-9274 40mg + Niacin 500mg', 'description': 'Participants received KPT-9274 40mg of oral tablet along with a starting dose of 500mg niacin ER orally three times a week every other day during each 28-day cycle.'}, {'id': 'OG007', 'title': 'Part B: KPT-9274 60mg + Niacin 500mg', 'description': 'Participants received KPT-9274 60mg of oral tablet along with a starting dose of 500mg niacin ER orally three times a week every other day during each 28-day cycle.'}, {'id': 'OG008', 'title': 'Part B: KPT-9274 80mg + Niacin 500mg', 'description': 'Participants received KPT-9274 80mg of oral tablet along with a starting dose of 500mg niacin ER orally three times a week every other day during each 28-day cycle.'}, {'id': 'OG009', 'title': 'Part B: KPT-9274 100mg + Niacin 500mg', 'description': 'Participants received KPT-9274 100mg of oral tablet along with a starting dose of 500mg niacin ER orally three times a week every other day during each 28-day cycle.'}, {'id': 'OG010', 'title': 'Part C: KPT-9274 20mg + Nivolumab 480mg', 'description': 'Participants received KPT-9274 20mg of oral tablet three times a week every other day during each 28-day cycle along with 480mg of nivolumab intravenous infusion on Day 1 of each cycle (once every 4-week cycle).'}, {'id': 'OG011', 'title': 'Part C: KPT-9274 30mg + Nivolumab 480mg', 'description': 'Participants received KPT-9274 30mg of oral tablet three times a week every other day during each 28-day cycle along with 480mg of nivolumab intravenous infusion on Day 1 of each cycle (once every 4-week cycle).'}, {'id': 'OG012', 'title': 'Part C: KPT-9274 40mg + Nivolumab 480mg', 'description': 'Participants received KPT-9274 40mg of oral tablet three times a week every other day during each 28-day cycle along with 480mg of nivolumab intravenous infusion on Day 1 of each cycle (once every 4-week cycle).'}], 'timeFrame': 'Cycle 1 and 2: Pre-dose, 3, 6, 8, 24, and 48 hours post-dose (each cycle =28 days)', 'description': 'The Vd/F was defined as MRT\\*CL/F, where MRT is the mean residence time (calculated as AUMC\\[0-tau\\]/AUC\\[0-tau\\], where AUMC\\[0-tau\\] is the area under the first moment curve determined as the area under the concentration\\*time versus time curve).', 'reportingStatus': 'POSTED', 'populationDescription': 'Study was terminated prematurely due to a lack of efficacy during primary analysis stage. Data for this outcome measure was not collected or analyzed as per planned analysis.'}, {'type': 'SECONDARY', 'title': 'Apparent Plasma Clearance (CL/F) in Participants Who Received KPT-9274', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}, {'value': '0', 'groupId': 'OG008'}, {'value': '0', 'groupId': 'OG009'}, {'value': '0', 'groupId': 'OG010'}, {'value': '0', 'groupId': 'OG011'}, {'value': '0', 'groupId': 'OG012'}]}], 'groups': [{'id': 'OG000', 'title': 'Part A: KPT-9274 10mg', 'description': 'Participants received 10mg of oral tablets of KPT-9274 three times a week every other day during each 28 day cycle.'}, {'id': 'OG001', 'title': 'Part A: KPT-9274 20mg', 'description': 'Participants received 20mg of oral tablets of KPT-9274 three times a week every other day during each 28 day cycle.'}, {'id': 'OG002', 'title': 'Part A: KPT-9274 30mg', 'description': 'Participants received 30mg of oral tablets of KPT-9274 three times a week every other day during each 28 day cycle.'}, {'id': 'OG003', 'title': 'Part A: KPT-9274 40mg', 'description': 'Participants received 40mg of oral tablets of KPT-9274 three times a week every other day during each 28 day cycle.'}, {'id': 'OG004', 'title': 'Part A: KPT-9274 40mg BIW', 'description': 'Participants received KPT-9274 40mg of oral tablet biweekly (BIW) during each 28-day cycle.'}, {'id': 'OG005', 'title': 'Part B: KPT-9274 30mg + Niacin 500mg', 'description': 'Participants received KPT-9274 30mg of oral tablet along with a starting dose of 500mg niacin extended release (ER) orally three times a week every other day during each 28-day cycle.'}, {'id': 'OG006', 'title': 'Part B: KPT-9274 40mg + Niacin 500mg', 'description': 'Participants received KPT-9274 40mg of oral tablet along with a starting dose of 500mg niacin ER orally three times a week every other day during each 28-day cycle.'}, {'id': 'OG007', 'title': 'Part B: KPT-9274 60mg + Niacin 500mg', 'description': 'Participants received KPT-9274 60mg of oral tablet along with a starting dose of 500mg niacin ER orally three times a week every other day during each 28-day cycle.'}, {'id': 'OG008', 'title': 'Part B: KPT-9274 80mg + Niacin 500mg', 'description': 'Participants received KPT-9274 80mg of oral tablet along with a starting dose of 500mg niacin ER orally three times a week every other day during each 28-day cycle.'}, {'id': 'OG009', 'title': 'Part B: KPT-9274 100mg + Niacin 500mg', 'description': 'Participants received KPT-9274 100mg of oral tablet along with a starting dose of 500mg niacin ER orally three times a week every other day during each 28-day cycle.'}, {'id': 'OG010', 'title': 'Part C: KPT-9274 20mg + Nivolumab 480mg', 'description': 'Participants received KPT-9274 20mg of oral tablet three times a week every other day during each 28-day cycle along with 480mg of nivolumab intravenous infusion on Day 1 of each cycle (once every 4-week cycle).'}, {'id': 'OG011', 'title': 'Part C: KPT-9274 30mg + Nivolumab 480mg', 'description': 'Participants received KPT-9274 30mg of oral tablet three times a week every other day during each 28-day cycle along with 480mg of nivolumab intravenous infusion on Day 1 of each cycle (once every 4-week cycle).'}, {'id': 'OG012', 'title': 'Part C: KPT-9274 40mg + Nivolumab 480mg', 'description': 'Participants received KPT-9274 40mg of oral tablet three times a week every other day during each 28-day cycle along with 480mg of nivolumab intravenous infusion on Day 1 of each cycle (once every 4-week cycle).'}], 'timeFrame': 'Cycle 1 and 2: Pre-dose, 3, 6, 8, 24, and 48 hours post-dose (each cycle =28 days)', 'description': 'The CL/F was calculated as the KPT-9274 dose administered divided by the area-under-the-curve of KPT-9274 plasma concentration versus (vs) time.', 'reportingStatus': 'POSTED', 'populationDescription': 'Study was terminated prematurely due to a lack of efficacy during primary analysis stage. Data for this outcome measure was not collected or analyzed as per planned analysis.'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'Part A: KPT-9274 10mg', 'description': 'Participants received 10 milligrams (mg) of oral tablets of KPT-9274 three times a week every other day during each 28 day cycle.'}, {'id': 'FG001', 'title': 'Part A: KPT-9274 20mg', 'description': 'Participants received 20mg of oral tablets of KPT-9274 three times a week every other day during each 28 day cycle.'}, {'id': 'FG002', 'title': 'Part A: KPT-9274 30mg', 'description': 'Participants received 30mg of oral tablets of KPT-9274 three times a week every other day during each 28 day cycle.'}, {'id': 'FG003', 'title': 'Part A: KPT-9274 40mg', 'description': 'Participants received 40mg of oral tablets of KPT-9274 three times a week every other day during each 28 day cycle.'}, {'id': 'FG004', 'title': 'Part A: KPT-9274 40mg BIW', 'description': 'Participants received KPT-9274 40mg of oral tablet biweekly (BIW) during each 28-day cycle.'}, {'id': 'FG005', 'title': 'Part B: KPT-9274 30mg + Niacin 500mg', 'description': 'Participants received KPT-9274 30mg of oral tablet along with a starting dose of 500mg niacin extended release (ER) orally three times a week every other day during each 28-day cycle'}, {'id': 'FG006', 'title': 'Part B: KPT-9274 40mg + Niacin 500mg', 'description': 'Participants received KPT-9274 40mg of oral tablet along with a starting dose of 500mg niacin ER orally three times a week every other day during each 28-day cycle'}, {'id': 'FG007', 'title': 'Part B: KPT-9274 60mg + Niacin 500mg', 'description': 'Participants received KPT-9274 60mg of oral tablet along with a starting dose of 500mg niacin ER orally three times a week every other day during each 28-day cycle'}, {'id': 'FG008', 'title': 'Part B: KPT-9274 80mg + Niacin 500mg', 'description': 'Participants received KPT-9274 80mg of oral tablet along with a starting dose of 500mg niacin ER orally three times a week every other day during each 28-day cycle'}, {'id': 'FG009', 'title': 'Part B: KPT-9274 100mg + Niacin 500mg', 'description': 'Participants received KPT-9274 100mg of oral tablet along with a starting dose of 500mg niacin ER orally three times a week every other day during each 28-day cycle'}, {'id': 'FG010', 'title': 'Part C: KPT-9274 20mg + Nivolumab 480mg', 'description': 'Participants received KPT-9274 20mg of oral tablet three times a week every other day during each 28-day cycle along with 480mg of nivolumab intravenous infusion on Day 1 of each cycle (once every 4-week cycle).'}, {'id': 'FG011', 'title': 'Part C: KPT-9274 30mg + Nivolumab 480mg', 'description': 'Participants received KPT-9274 30mg of oral tablet three times a week every other day during each 28-day cycle along with 480mg of nivolumab intravenous infusion on Day 1 of each cycle (once every 4-week cycle).'}, {'id': 'FG012', 'title': 'Part C: KPT-9274 40mg + Nivolumab 480mg', 'description': 'Participants received KPT-9274 40mg of oral tablet three times a week every other day during each 28-day cycle along with 480mg of nivolumab intravenous infusion on Day 1 of each cycle (once every 4-week cycle).'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '3'}, {'groupId': 'FG001', 'numSubjects': '3'}, {'groupId': 'FG002', 'numSubjects': '5'}, {'groupId': 'FG003', 'numSubjects': '7'}, {'groupId': 'FG004', 'numSubjects': '5'}, {'groupId': 'FG005', 'numSubjects': '3'}, {'groupId': 'FG006', 'numSubjects': '4'}, {'groupId': 'FG007', 'numSubjects': '12'}, {'groupId': 'FG008', 'numSubjects': '7'}, {'groupId': 'FG009', 'numSubjects': '1'}, {'groupId': 'FG010', 'numSubjects': '1'}, {'groupId': 'FG011', 'numSubjects': '5'}, {'groupId': 'FG012', 'numSubjects': '4'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '3'}, {'groupId': 'FG001', 'numSubjects': '3'}, {'groupId': 'FG002', 'numSubjects': '5'}, {'groupId': 'FG003', 'numSubjects': '7'}, {'groupId': 'FG004', 'numSubjects': '5'}, {'groupId': 'FG005', 'numSubjects': '3'}, {'groupId': 'FG006', 'numSubjects': '4'}, {'groupId': 'FG007', 'numSubjects': '12'}, {'groupId': 'FG008', 'numSubjects': '7'}, {'groupId': 'FG009', 'numSubjects': '1'}, {'groupId': 'FG010', 'numSubjects': '1'}, {'groupId': 'FG011', 'numSubjects': '5'}, {'groupId': 'FG012', 'numSubjects': '4'}]}], 'dropWithdraws': [{'type': 'Disease progression', 'reasons': [{'groupId': 'FG000', 'numSubjects': '3'}, {'groupId': 'FG001', 'numSubjects': '3'}, {'groupId': 'FG002', 'numSubjects': '2'}, {'groupId': 'FG003', 'numSubjects': '4'}, {'groupId': 'FG004', 'numSubjects': '4'}, {'groupId': 'FG005', 'numSubjects': '1'}, {'groupId': 'FG006', 'numSubjects': '2'}, {'groupId': 'FG007', 'numSubjects': '8'}, {'groupId': 'FG008', 'numSubjects': '5'}, {'groupId': 'FG009', 'numSubjects': '1'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '3'}, {'groupId': 'FG012', 'numSubjects': '2'}]}, {'type': 'Clinical progression', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '2'}, {'groupId': 'FG003', 'numSubjects': '1'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '2'}, {'groupId': 'FG006', 'numSubjects': '1'}, {'groupId': 'FG007', 'numSubjects': '4'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '1'}, {'groupId': 'FG011', 'numSubjects': '2'}, {'groupId': 'FG012', 'numSubjects': '0'}]}, {'type': 'Adverse Event', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '1'}, {'groupId': 'FG003', 'numSubjects': '2'}, {'groupId': 'FG004', 'numSubjects': '1'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '1'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '2'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '1'}]}, {'type': 'Other', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '1'}]}]}], 'recruitmentDetails': 'This study was conducted at 8 investigative sites in the United States and Canada from 08 Jun 2016 to 26 Jan 2021.', 'preAssignmentDetails': 'A total of 60 participants were enrolled and randomized to receive treatment in 2 phases, Dose Escalation (Part A \\[23 participants\\] and Part B \\[27 participants\\]; and Dose Expansion Phases (Part C \\[10 participants\\]). Study was terminated prematurely due to a lack of efficacy during primary analysis and therefore, efficacy, pharmacokinetic (PK) and pharmacodynamics (PDn) assessments were not determined.'}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'BG000'}, {'value': '3', 'groupId': 'BG001'}, {'value': '5', 'groupId': 'BG002'}, {'value': '7', 'groupId': 'BG003'}, {'value': '5', 'groupId': 'BG004'}, {'value': '3', 'groupId': 'BG005'}, {'value': '4', 'groupId': 'BG006'}, {'value': '12', 'groupId': 'BG007'}, {'value': '7', 'groupId': 'BG008'}, {'value': '1', 'groupId': 'BG009'}, {'value': '1', 'groupId': 'BG010'}, {'value': '5', 'groupId': 'BG011'}, {'value': '4', 'groupId': 'BG012'}, {'value': '60', 'groupId': 'BG013'}]}], 'groups': [{'id': 'BG000', 'title': 'Part A: KPT-9274 10mg', 'description': 'Participants received 10mg of oral tablets of KPT-9274 three times a week every other day during each 28 day cycle.'}, {'id': 'BG001', 'title': 'Part A: KPT-9274 20mg', 'description': 'Participants received 20mg of oral tablets of KPT-9274 three times a week every other day during each 28 day cycle.'}, {'id': 'BG002', 'title': 'Part A: KPT-9274 30mg', 'description': 'Participants received 30mg of oral tablets of KPT-9274 three times a week every other day during each 28 day cycle.'}, {'id': 'BG003', 'title': 'Part A: KPT-9274 40mg', 'description': 'Participants received 40mg of oral tablets of KPT-9274 three times a week every other day during each 28 day cycle.'}, {'id': 'BG004', 'title': 'Part A: KPT-9274 40mg BIW', 'description': 'Participants received KPT-9274 40mg of oral tablet BIW during each 28-day cycle.'}, {'id': 'BG005', 'title': 'Part B: KPT-9274 30mg + Niacin 500mg', 'description': 'Participants received KPT-9274 30mg of oral tablet along with a starting dose of 500mg niacin extended release (ER) orally three times a week every other day during each 28-day cycle.'}, {'id': 'BG006', 'title': 'Part B: KPT-9274 40mg + Niacin 500mg', 'description': 'Participants received KPT-9274 40mg of oral tablet along with a starting dose of 500mg niacin ER orally three times a week every other day during each 28-day cycle.'}, {'id': 'BG007', 'title': 'Part B: KPT-9274 60mg + Niacin 500mg', 'description': 'Participants received KPT-9274 60mg of oral tablet along with a starting dose of 500mg niacin ER orally three times a week every other day during each 28-day cycle.'}, {'id': 'BG008', 'title': 'Part B: KPT-9274 80mg + Niacin 500mg', 'description': 'Participants received KPT-9274 80mg of oral tablet along with a starting dose of 500mg niacin ER orally three times a week every other day during each 28-day cycle.'}, {'id': 'BG009', 'title': 'Part B: KPT-9274 100mg + Niacin 500mg', 'description': 'Participants received KPT-9274 100mg of oral tablet along with a starting dose of 500mg niacin ER orally three times a week every other day during each 28-day cycle'}, {'id': 'BG010', 'title': 'Part C: KPT-9274 20mg + Nivolumab 480mg', 'description': 'Participants received KPT-9274 20mg of oral tablet three times a week every other day during each 28-day cycle along with 480mg of nivolumab intravenous infusion on Day 1 of each cycle (once every 4-week cycle).'}, {'id': 'BG011', 'title': 'Part C: KPT-9274 30mg + Nivolumab 480mg', 'description': 'Participants received KPT-9274 30mg of oral tablet three times a week every other day during each 28-day cycle along with 480mg of nivolumab intravenous infusion on Day 1 of each cycle (once every 4-week cycle).'}, {'id': 'BG012', 'title': 'Part C: KPT-9274 40mg + Nivolumab 480mg', 'description': 'Participants received KPT-9274 40mg of oral tablet three times a week every other day during each 28-day cycle along with 480mg of nivolumab intravenous infusion on Day 1 of each cycle (once every 4-week cycle).'}, {'id': 'BG013', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'measures': [{'title': 'Age, Continuous', 'classes': [{'categories': [{'measurements': [{'value': '55.3', 'spread': '16.62', 'groupId': 'BG000'}, {'value': '63.7', 'spread': '3.21', 'groupId': 'BG001'}, {'value': '56.6', 'spread': '6.77', 'groupId': 'BG002'}, {'value': '59.6', 'spread': '17.17', 'groupId': 'BG003'}, {'value': '68.8', 'spread': '4.66', 'groupId': 'BG004'}, {'value': '44.0', 'spread': '14.73', 'groupId': 'BG005'}, {'value': '65.0', 'spread': '4.55', 'groupId': 'BG006'}, {'value': '61.8', 'spread': '9.69', 'groupId': 'BG007'}, {'value': '55.0', 'spread': '15.00', 'groupId': 'BG008'}, {'value': '38.0', 'spread': 'NA', 'comment': 'Standard deviation was not calculated, as there is only one participant enrolled in this arm.', 'groupId': 'BG009'}, {'value': '67.0', 'spread': 'NA', 'comment': 'Standard deviation was not calculated, as there is only one participant enrolled in this arm.', 'groupId': 'BG010'}, {'value': '63.6', 'spread': '14.36', 'groupId': 'BG011'}, {'value': '62.0', 'spread': '10.20', 'groupId': 'BG012'}, {'value': '59.8', 'spread': '12.26', 'groupId': 'BG013'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'Years', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '1', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '3', 'groupId': 'BG002'}, {'value': '2', 'groupId': 'BG003'}, {'value': '1', 'groupId': 'BG004'}, {'value': '1', 'groupId': 'BG005'}, {'value': '3', 'groupId': 'BG006'}, {'value': '6', 'groupId': 'BG007'}, {'value': '2', 'groupId': 'BG008'}, {'value': '0', 'groupId': 'BG009'}, {'value': '0', 'groupId': 'BG010'}, {'value': '5', 'groupId': 'BG011'}, {'value': '2', 'groupId': 'BG012'}, {'value': '26', 'groupId': 'BG013'}]}, {'title': 'Male', 'measurements': [{'value': '2', 'groupId': 'BG000'}, {'value': '3', 'groupId': 'BG001'}, {'value': '2', 'groupId': 'BG002'}, {'value': '5', 'groupId': 'BG003'}, {'value': '4', 'groupId': 'BG004'}, {'value': '2', 'groupId': 'BG005'}, {'value': '1', 'groupId': 'BG006'}, {'value': '6', 'groupId': 'BG007'}, {'value': '5', 'groupId': 'BG008'}, {'value': '1', 'groupId': 'BG009'}, {'value': '1', 'groupId': 'BG010'}, {'value': '0', 'groupId': 'BG011'}, {'value': '2', 'groupId': 'BG012'}, {'value': '34', 'groupId': 'BG013'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Ethnicity (NIH/OMB)', 'classes': [{'categories': [{'title': 'Hispanic or Latino', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '0', 'groupId': 'BG005'}, {'value': '0', 'groupId': 'BG006'}, {'value': '2', 'groupId': 'BG007'}, {'value': '0', 'groupId': 'BG008'}, {'value': '0', 'groupId': 'BG009'}, {'value': '0', 'groupId': 'BG010'}, {'value': '0', 'groupId': 'BG011'}, {'value': '0', 'groupId': 'BG012'}, {'value': '2', 'groupId': 'BG013'}]}, {'title': 'Not Hispanic or Latino', 'measurements': [{'value': '3', 'groupId': 'BG000'}, {'value': '3', 'groupId': 'BG001'}, {'value': '4', 'groupId': 'BG002'}, {'value': '5', 'groupId': 'BG003'}, {'value': '5', 'groupId': 'BG004'}, {'value': '2', 'groupId': 'BG005'}, {'value': '4', 'groupId': 'BG006'}, {'value': '8', 'groupId': 'BG007'}, {'value': '5', 'groupId': 'BG008'}, {'value': '0', 'groupId': 'BG009'}, {'value': '1', 'groupId': 'BG010'}, {'value': '5', 'groupId': 'BG011'}, {'value': '4', 'groupId': 'BG012'}, {'value': '49', 'groupId': 'BG013'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '1', 'groupId': 'BG002'}, {'value': '2', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '1', 'groupId': 'BG005'}, {'value': '0', 'groupId': 'BG006'}, {'value': '2', 'groupId': 'BG007'}, {'value': '2', 'groupId': 'BG008'}, {'value': '1', 'groupId': 'BG009'}, {'value': '0', 'groupId': 'BG010'}, {'value': '0', 'groupId': 'BG011'}, {'value': '0', 'groupId': 'BG012'}, {'value': '9', 'groupId': 'BG013'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Race (NIH/OMB)', 'classes': [{'categories': [{'title': 'American Indian or Alaska Native', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '1', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '0', 'groupId': 'BG005'}, {'value': '0', 'groupId': 'BG006'}, {'value': '0', 'groupId': 'BG007'}, {'value': '0', 'groupId': 'BG008'}, {'value': '0', 'groupId': 'BG009'}, {'value': '0', 'groupId': 'BG010'}, {'value': '0', 'groupId': 'BG011'}, {'value': '0', 'groupId': 'BG012'}, {'value': '1', 'groupId': 'BG013'}]}, {'title': 'Asian', 'measurements': [{'value': '1', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '1', 'groupId': 'BG004'}, {'value': '1', 'groupId': 'BG005'}, {'value': '0', 'groupId': 'BG006'}, {'value': '1', 'groupId': 'BG007'}, {'value': '1', 'groupId': 'BG008'}, {'value': '0', 'groupId': 'BG009'}, {'value': '0', 'groupId': 'BG010'}, {'value': '0', 'groupId': 'BG011'}, {'value': '0', 'groupId': 'BG012'}, {'value': '5', 'groupId': 'BG013'}]}, {'title': 'Native Hawaiian or Other Pacific Islander', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '0', 'groupId': 'BG005'}, {'value': '0', 'groupId': 'BG006'}, {'value': '0', 'groupId': 'BG007'}, {'value': '0', 'groupId': 'BG008'}, {'value': '0', 'groupId': 'BG009'}, {'value': '0', 'groupId': 'BG010'}, {'value': '0', 'groupId': 'BG011'}, {'value': '0', 'groupId': 'BG012'}, {'value': '0', 'groupId': 'BG013'}]}, {'title': 'Black or African American', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '1', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '0', 'groupId': 'BG005'}, {'value': '0', 'groupId': 'BG006'}, {'value': '1', 'groupId': 'BG007'}, {'value': '0', 'groupId': 'BG008'}, {'value': '0', 'groupId': 'BG009'}, {'value': '0', 'groupId': 'BG010'}, {'value': '1', 'groupId': 'BG011'}, {'value': '1', 'groupId': 'BG012'}, {'value': '4', 'groupId': 'BG013'}]}, {'title': 'White', 'measurements': [{'value': '2', 'groupId': 'BG000'}, {'value': '3', 'groupId': 'BG001'}, {'value': '3', 'groupId': 'BG002'}, {'value': '5', 'groupId': 'BG003'}, {'value': '4', 'groupId': 'BG004'}, {'value': '2', 'groupId': 'BG005'}, {'value': '4', 'groupId': 'BG006'}, {'value': '10', 'groupId': 'BG007'}, {'value': '5', 'groupId': 'BG008'}, {'value': '1', 'groupId': 'BG009'}, {'value': '1', 'groupId': 'BG010'}, {'value': '4', 'groupId': 'BG011'}, {'value': '3', 'groupId': 'BG012'}, {'value': '47', 'groupId': 'BG013'}]}, {'title': 'More than one race', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '0', 'groupId': 'BG005'}, {'value': '0', 'groupId': 'BG006'}, {'value': '0', 'groupId': 'BG007'}, {'value': '1', 'groupId': 'BG008'}, {'value': '0', 'groupId': 'BG009'}, {'value': '0', 'groupId': 'BG010'}, {'value': '0', 'groupId': 'BG011'}, {'value': '0', 'groupId': 'BG012'}, {'value': '1', 'groupId': 'BG013'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '1', 'groupId': 'BG002'}, {'value': '1', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '0', 'groupId': 'BG005'}, {'value': '0', 'groupId': 'BG006'}, {'value': '0', 'groupId': 'BG007'}, {'value': '0', 'groupId': 'BG008'}, {'value': '0', 'groupId': 'BG009'}, {'value': '0', 'groupId': 'BG010'}, {'value': '0', 'groupId': 'BG011'}, {'value': '0', 'groupId': 'BG012'}, {'value': '2', 'groupId': 'BG013'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}], 'populationDescription': 'The safety population consisted of all participants who had received at least 1 dose of the study treatment. Participants were analyzed according to the treatment they received.'}}, 'documentSection': {'largeDocumentModule': {'largeDocs': [{'date': '2020-03-11', 'size': 4969400, 'label': 'Study Protocol', 'hasIcf': False, 'hasSap': False, 'filename': 'Prot_000.pdf', 'typeAbbrev': 'Prot', 'uploadDate': '2023-08-17T07:51', 'hasProtocol': True}, {'date': '2021-09-08', 'size': 996565, 'label': 'Statistical Analysis Plan', 'hasIcf': False, 'hasSap': True, 'filename': 'SAP_001.pdf', 'typeAbbrev': 'SAP', 'uploadDate': '2023-08-17T07:54', 'hasProtocol': False}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE1'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NON_RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'SINGLE_GROUP'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 60}}, 'statusModule': {'whyStopped': 'sponsor decision', 'overallStatus': 'TERMINATED', 'startDateStruct': {'date': '2016-06-08', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2024-10', 'completionDateStruct': {'date': '2021-01-26', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2024-10-03', 'studyFirstSubmitDate': '2016-03-03', 'resultsFirstSubmitDate': '2023-08-17', 'studyFirstSubmitQcDate': '2016-03-03', 'lastUpdatePostDateStruct': {'date': '2024-11-25', 'type': 'ACTUAL'}, 'resultsFirstSubmitQcDate': '2024-10-03', 'studyFirstPostDateStruct': {'date': '2016-03-08', 'type': 'ESTIMATED'}, 'resultsFirstPostDateStruct': {'date': '2024-11-25', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2021-01-26', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Maximum Tolerated Dose (MTD) for KPT-9274', 'timeFrame': 'From start of study drug administration up to 44 weeks', 'description': 'The MTD was defined as the highest dose at which less than or equal to (\\<=) 1 participant experienced a dose limiting toxicity (DLT) in Cycle 1. A DLT was defined as an adverse event (AE) or abnormal laboratory value occurring within the first 28 days of treatment of KPT-9274, excluding those clearly caused by underlying disease, disease progression, or external factors.'}, {'measure': 'Number of Dose Limiting Toxicities (DLT) Experienced by Participants', 'timeFrame': 'At Cycle 1 only (28-day cycle)', 'description': 'A DLT was defined as an AE or abnormal laboratory value occurring within the first 28 days of KPT-9274 treatment, excluding those clearly caused by underlying disease, disease progression, or extraneous causes, and meets any of the criteria for defining dose limiting toxicities.'}, {'measure': 'Number of Participants With Adverse Event (AE) of Severity Grade >= 3 or 4, Serious AEs, and AEs Leading to Treatment Discontinuation', 'timeFrame': 'From start of study drug administration up to 49 weeks', 'description': 'The AE severity was graded on a scale from 1 to 4 using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.03; any events not specifically listed in the scale were defined as: Grade 1 is mild; Grade 2 is moderate; Grade 3 is severe or medically significant; Grade 4 is life-threatening. An SAE was any untoward medical occurrence that at any dose met one, more of the following criteria: results in death, life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent, significant disability/incapacity, a congenital abnormality/birth defect, an important medical event. The AE leading to treatment discontinuation in the study.'}, {'measure': 'Percentage of Participants With Overall Response Rate (ORR)', 'timeFrame': 'From date of randomization up to 44 weeks', 'description': 'The ORR was defined as percentage of participants who had a response of partial response (PR) or complete response (CR). The PR was achieved when a participant had at least a 30 percent (%) decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. The CR was achieved in a participant when all target lesions disappeared. Any pathological lymph nodes (whether target or non target) must have reduction in the short axis to \\<10 millimeter (mm).'}, {'measure': 'Percentage of Participants With Disease Control Rate (DCR)', 'timeFrame': 'From date of the first study treatment up to 44 weeks', 'description': 'The DCR was defined as percentage of participants who have a response of CR, PR, and stable disease (SD) \\>= 16 weeks, DCR = CR + PR+ SD. The PR was achieved when a participant had at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. The CR was achieved in a participant when all target lesions disappeared. Any pathological lymph nodes (whether target or non-target) must have reduction in the short axis to \\<10mm. The SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD).'}, {'measure': 'Progression-free Survival (PFS)', 'timeFrame': 'From the date of first study treatment until the first date of PD, or death due (up to 44 weeks)', 'description': 'The PFS was defined as the duration of time from date of the first study treatment until the first date that PD is objectively documented or death due to any cause. The PD is defined as at least a 20% increase in the sum of diameters of measured lesions taking as references the smallest sum of diameters recorded since the treatment started. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5mm. Appearance of one or more new lesions will also constitute PD.'}, {'measure': 'Overall Survival (OS)', 'timeFrame': 'From date of the first study treatment until death (up to 44 weeks)', 'description': 'The OS was defined as the duration of time from date of the first study treatment until death from any cause.'}, {'measure': 'Time to Progression (TTP)', 'timeFrame': 'From date of the first study treatment until the first date of PD or death (up to 44 weeks)', 'description': 'The TTP was defined as the duration of time from date of the first study treatment until the first date that PD was objectively documented or death due to PD.'}, {'measure': 'Duration of Response (DOR)', 'timeFrame': 'Up to 44 weeks', 'description': 'The DOR was defined as the duration of time from the first meeting CR or PR measurement criteria (whichever occurs first) until the first date diseases progression.'}], 'secondaryOutcomes': [{'measure': 'Maximum Plasma Concentration (Cmax) in Participants Who Received KPT-9274', 'timeFrame': 'Cycle 1 and 2: Pre-dose, 3, 6, 8, 24, and 48 hours post-dose (each cycle =28 days)', 'description': 'Cmax achieved by the KPT-9274 after the first dose administrations.'}, {'measure': 'Time-to-peak Plasma Concentration (Tmax) in Participants Who Received KPT-9274', 'timeFrame': 'Cycle 1 and 2: Pre-dose, 3, 6, 8, 24, and 48 hours post-dose (each cycle =28 days)', 'description': 'Time taken by KPT-9274 to achieve maximum plasma concentration after the first dose administration.'}, {'measure': 'Terminal Half-life (T1/2) in Participants Who Received KPT-9274', 'timeFrame': 'Cycle 1 and 2: Pre-dose, 3, 6, 8, 24, and 48 hours post-dose (each cycle =28 days)', 'description': 'The T1/2 was defied as the time it takes for the concentration of KPT-9274 in the plasma to be reduced by 50%.'}, {'measure': 'Volume of Distribution (Vd/F) in Participants Who Received KPT-9274', 'timeFrame': 'Cycle 1 and 2: Pre-dose, 3, 6, 8, 24, and 48 hours post-dose (each cycle =28 days)', 'description': 'The Vd/F was defined as MRT\\*CL/F, where MRT is the mean residence time (calculated as AUMC\\[0-tau\\]/AUC\\[0-tau\\], where AUMC\\[0-tau\\] is the area under the first moment curve determined as the area under the concentration\\*time versus time curve).'}, {'measure': 'Apparent Plasma Clearance (CL/F) in Participants Who Received KPT-9274', 'timeFrame': 'Cycle 1 and 2: Pre-dose, 3, 6, 8, 24, and 48 hours post-dose (each cycle =28 days)', 'description': 'The CL/F was calculated as the KPT-9274 dose administered divided by the area-under-the-curve of KPT-9274 plasma concentration versus (vs) time.'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['PAK4', 'KPT-9274', 'Karyopharm', 'NHL', 'Solid Tumors', 'NAMPT', 'Melanoma'], 'conditions': ['Solid Tumors', 'NHL']}, 'referencesModule': {'references': [{'pmid': '37864885', 'type': 'DERIVED', 'citation': 'Han W, Yang Y, Yu F, Li Q, Liu A, Xu W, Li J, Xue X. Design, synthesis and anticancer activity evaluation of 4-(3-1H-indazolyl)amino quinazoline derivatives as PAK4 inhibitors. Bioorg Med Chem. 2023 Nov 15;95:117501. doi: 10.1016/j.bmc.2023.117501. Epub 2023 Oct 13.'}, {'pmid': '34253597', 'type': 'DERIVED', 'citation': 'Mpilla GB, Uddin MH, Al-Hallak MN, Aboukameel A, Li Y, Kim SH, Beydoun R, Dyson G, Baloglu E, Senapedis WT, Landesman Y, Wagner KU, Viola NT, El-Rayes BF, Philip PA, Mohammad RM, Azmi AS. PAK4-NAMPT Dual Inhibition Sensitizes Pancreatic Neuroendocrine Tumors to Everolimus. Mol Cancer Ther. 2021 Oct;20(10):1836-1845. doi: 10.1158/1535-7163.MCT-20-1105. Epub 2021 Jul 12.'}, {'pmid': '28062705', 'type': 'DERIVED', 'citation': 'Aboukameel A, Muqbil I, Senapedis W, Baloglu E, Landesman Y, Shacham S, Kauffman M, Philip PA, Mohammad RM, Azmi AS. Novel p21-Activated Kinase 4 (PAK4) Allosteric Modulators Overcome Drug Resistance and Stemness in Pancreatic Ductal Adenocarcinoma. Mol Cancer Ther. 2017 Jan;16(1):76-87. doi: 10.1158/1535-7163.MCT-16-0205. Epub 2016 Nov 15.'}]}, 'descriptionModule': {'briefSummary': "This study will evaluate the safety, tolerability, and efficacy of oral KPT-9274 for the treatment of patients with advanced solid malignancies or non-Hodgkin's lymphoma (NHL).", 'detailedDescription': 'This is a first-in-human, multi-center, open-label clinical study with separate Dose Escalation and Expansion Phases to assess preliminary safety, tolerability, and efficacy of KPT-9274, a dual inhibitor of PAK4 and NAMPT, in patients with advanced solid malignancies (including sarcoma, colon, lung, melanoma, etc.) or NHL for which all standard therapeutic options considered useful by the investigator have been exhausted.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': "Inclusion Criteria:\n\nParticipants must meet all of the following inclusion criteria to be eligible to enroll in the Part C of this study.\n\n1. Should have unresectable advanced, recurrent or metastatic melanoma and must have objective and measurable melanoma by RECIST 1.1 after disease progression on a prior anti-PD-1 or anti-PD-L1 therapy.\n2. ECOG performance status of ≤ 2.\n3. Life expectancy of ≥ 3 months.\n4. Adequate hepatic function:\n\n * Total bilirubin \\< 1.5 times the ULN (except participants with Gilbert's syndrome \\[hereditary indirect hyperbilirubinemia\\] who must have a total bilirubin of ≤ 3 times ULN),\n * AST and ALT ≤ 2.5 times ULN (except participants with known liver involvement of their advanced solid malignancy who must have an AST and ALT ≤ 5.0 times ULN).\n5. Adequate renal function:\n\n * Estimated creatinine clearance of ≥ 60 mL/min, calculated using the formula of Cockroft and Gault (140-Age) Mass (kg)/(72 creatinine mg/dL); multiply by 0.85 if female.\n6. Adequate hematopoietic function:\n\n * Total WBC count ≥ 1500/mm³, ANC ≥ 1000/mm³, Hb ≥ 10.0 g/dL, platelet count ≥ 100,000/mm³\n\nExclusion Criteria:\n\nParticipants meeting any of the following exclusion criteria are not eligible to enroll in this study.\n\n1. ≤ 2 weeks since the last prior therapeutic regimen for melanoma. Palliative steroids for disease related symptoms \\< 7 days prior to C1D1, unless physiologic doses of steroids are used.\n2. Have not recovered or stabilized (Gr 1 or to their baseline for non-hematologic toxicities, ≤ Gr 2 or to their baseline for hematologic toxicities) from toxicities related to their previous treatment except for alopecia.\n3. Untreated CNS disease or leptomeningeal involvement are excluded. Participants without active brain or leptomeningeal metastases after prior treatment with local therapies are eligible provided that the treatment had been done ≥ 2 weeks prior to enrollment.\n4. Active infection with completion of therapeutic antibiotics, antivirals, or antifungals within one week prior to C1D1. Prophylactic antibiotics, antivirals or antifungals are permitted.\n5. Significantly diseased or obstructed gastrointestinal tract or uncontrolled vomiting or diarrhea that could interfere with the absorption of KPT-9274.\n6. Active peptic ulcer disease or other active gastrointestinal bleeds.\n7. Requiring treatment with corticosteroids at doses higher than substitute therapy (\\> 10 mg prednisone), are unstable with substitute hormonal therapy, or are deemed to be likely to re-occur by the treating physician when administered nivolumab."}, 'identificationModule': {'nctId': 'NCT02702492', 'acronym': 'PANAMA', 'briefTitle': 'PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA)', 'organization': {'class': 'INDUSTRY', 'fullName': 'Karyopharm Therapeutics Inc'}, 'officialTitle': "A Phase 1 Open-Label Study of the Safety, Tolerability and Efficacy of KPT-9274, a Dual Inhibitor of PAK4 and NAMPT, in Patients With Advanced Solid Malignancies or Non-Hodgkin's Lymphoma", 'orgStudyIdInfo': {'id': 'KCP-9274-901'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Part A: KPT-9274 10mg', 'description': 'Participants received a 10 milligrams (mg) of oral tablets of KPT-9274 three times a week every other day during each 28 day cycle.', 'interventionNames': ['Drug: KPT-9274']}, {'type': 'EXPERIMENTAL', 'label': 'Part A: KPT-9274 20mg', 'description': 'Participants received a 20mg of oral tablets of KPT-9274 three times a week every other day during each 28 day cycle.', 'interventionNames': ['Drug: KPT-9274']}, {'type': 'EXPERIMENTAL', 'label': 'Part A: KPT-9274 30mg', 'description': 'Participants received a 30mg of oral tablets of KPT-9274 three times a week every other day during each 28 day cycle.', 'interventionNames': ['Drug: KPT-9274']}, {'type': 'EXPERIMENTAL', 'label': 'Part A: KPT-9274 40mg', 'description': 'Participants received a 40mg of oral tablets of KPT-9274 three times a week every other day during each 28 day cycle.', 'interventionNames': ['Drug: KPT-9274']}, {'type': 'EXPERIMENTAL', 'label': 'Part A: KPT-9274 40mg BIW', 'description': 'Participants received KPT-9274 40mg of oral tablet biweekly (BIW) during each 28-day cycle.', 'interventionNames': ['Drug: KPT-9274']}, {'type': 'EXPERIMENTAL', 'label': 'Part B: KPT-9274 30mg + Niacin 500mg', 'description': 'Participants received KPT-9274 30mg of oral tablet along with a starting dose of 500mg niacin extended release (ER) orally three times a week every other day during each 28-day cycle.', 'interventionNames': ['Drug: KPT-9274', 'Drug: Niacin ER']}, {'type': 'EXPERIMENTAL', 'label': 'Part B: KPT-9274 40mg + Niacin 500mg', 'description': 'Participants received KPT-9274 40mg of oral tablet along with a starting dose of 500mg niacin ER orally three times a week every other day during each 28-day cycle.', 'interventionNames': ['Drug: KPT-9274', 'Drug: Niacin ER']}, {'type': 'EXPERIMENTAL', 'label': 'Part B: KPT-9274 60mg + Niacin 500mg', 'description': 'Participants received KPT-9274 60mg of oral tablet along with a starting dose of 500mg niacin ER orally three times a week every other day during each 28-day cycle.', 'interventionNames': ['Drug: KPT-9274', 'Drug: Niacin ER']}, {'type': 'EXPERIMENTAL', 'label': 'Part B: KPT-9274 80mg + Niacin 500mg', 'description': 'Participants received KPT-9274 80mg of oral tablet along with a starting dose of 500mg niacin ER orally three times a week every other day during each 28-day cycle.', 'interventionNames': ['Drug: KPT-9274', 'Drug: Niacin ER']}, {'type': 'EXPERIMENTAL', 'label': 'Part B: KPT-9274 100mg + Niacin 500mg', 'description': 'Participants received KPT-9274 100mg of oral tablet along with a starting dose of 500mg niacin ER orally three times a week every other day during each 28-day cycle.', 'interventionNames': ['Drug: KPT-9274', 'Drug: Niacin ER']}, {'type': 'EXPERIMENTAL', 'label': 'Part C: KPT-9274 20mg + Nivolumab 480mg', 'description': 'Participants received KPT-9274 20mg of oral tablet three times a week every other day during each 28-day cycle along with 480mg of nivolumab intravenous infusion on Day 1 of each cycle (once every 4-week cycle).', 'interventionNames': ['Drug: KPT-9274', 'Drug: Nivolumab']}, {'type': 'EXPERIMENTAL', 'label': 'Part C: KPT-9274 30mg + Nivolumab 480mg', 'description': 'Participants received KPT-9274 30mg of oral tablet three times a week every other day during each 28-day cycle along with 480mg of nivolumab intravenous infusion on Day 1 of each cycle (once every 4-week cycle).', 'interventionNames': ['Drug: KPT-9274', 'Drug: Nivolumab']}, {'type': 'EXPERIMENTAL', 'label': 'Part C: KPT-9274 40mg + Nivolumab 480mg', 'description': 'Participants received KPT-9274 40mg of oral tablet three times a week every other day during each 28-day cycle along with 480mg of nivolumab intravenous infusion on Day 1 of each cycle (once every 4-week cycle).', 'interventionNames': ['Drug: KPT-9274', 'Drug: Nivolumab']}], 'interventions': [{'name': 'KPT-9274', 'type': 'DRUG', 'armGroupLabels': ['Part A: KPT-9274 10mg', 'Part A: KPT-9274 20mg', 'Part A: KPT-9274 30mg', 'Part A: KPT-9274 40mg', 'Part A: KPT-9274 40mg BIW', 'Part B: KPT-9274 100mg + Niacin 500mg', 'Part B: KPT-9274 30mg + Niacin 500mg', 'Part B: KPT-9274 40mg + Niacin 500mg', 'Part B: KPT-9274 60mg + Niacin 500mg', 'Part B: KPT-9274 80mg + Niacin 500mg', 'Part C: KPT-9274 20mg + Nivolumab 480mg', 'Part C: KPT-9274 30mg + Nivolumab 480mg', 'Part C: KPT-9274 40mg + Nivolumab 480mg']}, {'name': 'Niacin ER', 'type': 'DRUG', 'armGroupLabels': ['Part B: KPT-9274 100mg + Niacin 500mg', 'Part B: KPT-9274 30mg + Niacin 500mg', 'Part B: KPT-9274 40mg + Niacin 500mg', 'Part B: KPT-9274 60mg + Niacin 500mg', 'Part B: KPT-9274 80mg + Niacin 500mg']}, {'name': 'Nivolumab', 'type': 'DRUG', 'otherNames': ['Opdivo®'], 'armGroupLabels': ['Part C: KPT-9274 20mg + Nivolumab 480mg', 'Part C: KPT-9274 30mg + Nivolumab 480mg', 'Part C: KPT-9274 40mg + Nivolumab 480mg']}]}, 'contactsLocationsModule': {'locations': [{'zip': '90024', 'city': 'Los Angeles', 'state': 'California', 'country': 'United States', 'facility': 'UCLA Health', 'geoPoint': {'lat': 34.05223, 'lon': -118.24368}}, {'zip': '80045', 'city': 'Aurora', 'state': 'Colorado', 'country': 'United States', 'facility': 'University of Colorado Cancer Center', 'geoPoint': {'lat': 39.72943, 'lon': -104.83192}}, {'zip': '20007', 'city': 'Washington D.C.', 'state': 'District of Columbia', 'country': 'United States', 'facility': 'Georgetown University, Lombardi Comprehensive Cancer Center', 'geoPoint': {'lat': 38.89511, 'lon': -77.03637}}, {'zip': '55905', 'city': 'Rochester', 'state': 'Minnesota', 'country': 'United States', 'facility': 'Mayo Clinic Rochester', 'geoPoint': {'lat': 44.02163, 'lon': -92.4699}}, {'zip': '100016', 'city': 'New York', 'state': 'New York', 'country': 'United States', 'facility': 'NYU-Laura & Isaac Perlmutter Cancer Center', 'geoPoint': {'lat': 40.71427, 'lon': -74.00597}}, {'zip': '37232', 'city': 'Nashville', 'state': 'Tennessee', 'country': 'United States', 'facility': 'Vanderbilt-Ingram Cancer Center', 'geoPoint': {'lat': 36.16589, 'lon': -86.78444}}, {'zip': '77030', 'city': 'Houston', 'state': 'Texas', 'country': 'United States', 'facility': 'MD Anderson Cancer Center', 'geoPoint': {'lat': 29.76328, 'lon': -95.36327}}, {'zip': 'M5G 2M9', 'city': 'Toronto', 'state': 'Ontario', 'country': 'Canada', 'facility': 'Princess Margaret Hospital', 'geoPoint': {'lat': 43.70643, 'lon': -79.39864}}]}, 'ipdSharingStatementModule': {'ipdSharing': 'UNDECIDED'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Karyopharm Therapeutics Inc', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}